Any feedback?
Information on EC 3.5.2.2 - dihydropyrimidinase and Organism(s) Homo sapiens
for references in articles please use BRENDA:EC3.5.2.2Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
3.5.2.2 dihydropyrimidinaseIUBMB Comments
Also acts on dihydrothymine and hydantoin.
Specify your search results
Word Map
- 3.5.2.2
- 5-fluorouracil
- thymidylate
-
dihydropyridine
- colorectal
-
fluoropyrimidine
- phosphorylase
- thymidine
- capecitabine
-
l-type
- uracil
- nifedipine
- orotate
-
resect
-
blocker
-
pharmacogenetic
-
1,4-dihydropyridine
-
tegafur
-
prodrugs
-
voltage-dependent
- dihydrouracil
-
5-fu-based
-
fluoropyrimidine-based
-
nitrendipine
- leucovorin
-
phosphoribosyltransferase
- diltiazem
- oxaliplatin
- irinotecan
-
hemoperfusion
-
phosphoribosyl
-
5-fluorouracil-based
- mucositis
- neutropenia
-
pyrrolizidine
- 11-ketotestosterone
-
excitation-contraction
- isradipine
- nisoldipine
-
coniferyl
-
5-fu-induced
-
dihydropyridine-sensitive
- felodipine
-
5\'-dfur
- dihydroorotase
-
photochromic
- nicardipine
- synthesis
- industry
- 5'-deoxy-5-fluorouridine
-
pretherapeutic
-
omega-conotoxin
- nutrition
- medicine
-
hand-foot
The taxonomic range for the selected organisms is: Homo sapiens
The expected taxonomic range for this enzyme is: Bacteria, Archaea, Eukaryota
The expected taxonomic range for this enzyme is: Bacteria, Archaea, Eukaryota
Synonyms
dhp, dihydropyrimidine dehydrogenase, dihydropyrimidinase, hydantoinase, d-hydantoinase, dhp-1, dhpase, dihydropyrimidine amidohydrolase, dhp-2, padhpase, 
more
topPlease wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYNONYM 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
D-hydantoinase
-
-
-
-
DHP
Dihydropyrimidinase
-
-
-
-
hydantoin peptidase
-
-
-
-
hydantoinase
-
-
-
-
hydropyrimidine hydrase
-
-
-
-
pyrimidine hydrase
-
-
-
-
DHP
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
carboxylic acid amide hydrolysis
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PATHWAY SOURCE
PATHWAYS
KEGG
-
-, -
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYSTEMATIC NAME
IUBMB Comments
5,6-dihydropyrimidine amidohydrolase
Also acts on dihydrothymine and hydantoin.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CAS REGISTRY NUMBER
COMMENTARY
9030-74-4
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBSTRATE
PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Acquired Immunodeficiency Syndrome
Dihydropyrene as an Aromaticity Probe for Partially Quinoid Push-Pull Systems.
adenine phosphoribosyltransferase deficiency
Automated screening system for purine and pyrimidine metabolism disorders using high-performance liquid chromatography.
Adenocarcinoma
A unique case of a patient with rectal cancer who developed benign esophageal stenosis after localized rectal radiation and systemic chemotherapy.
Adenocarcinoma
Expression of dihydropyrimidine dehydrogenase in cancer cells but not in stromal cells predicts the efficacy of fluorouracil treatment in patients with gastric carcinoma.
Adenocarcinoma
Prognostic impact of dihydropyrimidine dehydrogenase expression on pancreatic adenocarcinoma patients treated with S-1-based adjuvant chemotherapy after surgical resection.
Adenocarcinoma
Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine.
Adenocarcinoma
[A Recurrent Case of Thymic Adenocarcinoma Effectively Treated with S-1 Over a Long-Term Period].
Adenocarcinoma
[Expression of dihydropyrimidine dehydrogenase negatively correlated with the prognosis of pancreatic ductal adenocarcinoma].
Adenocarcinoma
[Selection of anticancer drug for poorly-differentiated adenocarcinoma of colorectum from the level of orotate phosphoribosyl transferase and dihydropyrimidine dehydrogenase activities in cancer tissue]
Adenocarcinoma of Lung
Comparison of 5-fluorouracil-related gene expression levels between adenocarcinomas and squamous cell carcinomas of the lung.
Adenocarcinoma of Lung
High expression of dihydropyrimidine dehydrogenase in lung adenocarcinoma is associated with mutations in epidermal growth factor receptor: implications for the treatment of non--small-cell lung cancer using 5-fluorouracil.
Adenocarcinoma of Lung
Low dihydropyrimidine dehydrogenase correlates with prolonged survival in patients with lung adenocarcinoma treated with 5-fluorouracil.
Adenocarcinoma, Scirrhous
Clinical application of immunoreactivity of dihydropyrimidine dehydrogenase (DPD) in gastric scirrhous carcinoma treated with S-1, a new DPD inhibitory fluoropyrimidine.
adenylosuccinate lyase deficiency
Automated screening system for purine and pyrimidine metabolism disorders using high-performance liquid chromatography.
adenylosuccinate lyase deficiency
Metabolic approaches to the treatment of autism spectrum disorders.
adenylosuccinate lyase deficiency
Rapid screening of high-risk patients for disorders of purine and pyrimidine metabolism using HPLC-electrospray tandem mass spectrometry of liquid urine or urine-soaked filter paper strips.
adenylosuccinate lyase deficiency
Thirteen years experience with selective screening for disorders in purine and pyrimidine metabolism.
Albuminuria
Dihydropyridine calcium antagonists are associated with increased albuminuria in treatment-resistant hypertensives.
Alopecia
The effect of L-3, 4-dehydroproline on the antitumor activity and toxicity of bleomycin.
Alzheimer Disease
Expression of the dihydropyrimidinase related protein 2 (DRP-2) in Down syndrome and Alzheimer's disease brain is downregulated at the mRNA and dysregulated at the protein level.
Alzheimer Disease
Multi-target 1,4-dihydropyridines showing calcium channel blockade and antioxidant capacity for Alzheimer's disease therapy.
Anemia
Introducing post-discharge malaria chemoprevention (PMC) for management of severe anemia in Malawian children: a qualitative study of community health workers' perceptions and motivation.
Anhedonia
A role for the extracellular signal-regulated kinase signal pathway in depressive-like behavior.
Aphasia
Differences in factors influencing the use of eRehabilitation after stroke; a cross-sectional comparison between Brazilian and Dutch healthcare professionals.
Arrhythmias, Cardiac
[Dependence of mean duration of heart period and of arrhythmia during dynamic muscular work on the greatness and differences of work load and during static muscular work on the greatness of work load (author's transl)]
Atrial Fibrillation
Image Quality and Radiation Exposure Comparison of a Double High-Pitch Acquisition for Coronary Computed Tomography Angiography Versus Standard Retrospective Spiral Acquisition in Patients With Atrial Fibrillation.
Bacterial Infections
Dual-Action Biomaterial Surfaces with Quorum Sensing Inhibitor and Nitric Oxide To Reduce Bacterial Colonization.
Bacterial Infections
Enhancement of phagocytosis and bactericidal activity of neutrophils in miniature pigs by dihydroheptaprenol, a synthetic polyprenol derivative.
beta-ureidopropionase deficiency
Screening and diagnosis of beta-ureidopropionase deficiency by gas chromatographic/mass spectrometric analysis of urine.
Biliary Tract Neoplasms
Deficient expression of the DPD gene is caused by epigenetic modification in biliary tract cancer cells, and induces high sensitivity to 5-FU treatment.
Biliary Tract Neoplasms
Eastern Canadian Gastrointestinal Cancer Consensus Conference 2019.
Biliary Tract Neoplasms
Prognostic significance of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in biliary tract cancer patients receiving adjuvant 5-fluorouracil-based chemotherapy.
Biliary Tract Neoplasms
Thymidylate synthase and dihydropyrimidine dehydrogenase are upregulated in pancreatic and biliary tract cancers.
Brain Diseases
Hyperammonemic encephalopathy during XELOX regimen. Is it capecitabine or oxaliplatin responsible?
Breast Neoplasms
Antihypertensive agents and the risk of breast cancer in women aged 55 years and older: a nested case-control study.
Breast Neoplasms
Capecitabine: indications and future perspectives in the treatment of metastatic colorectal and breast cancer.
Breast Neoplasms
Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients.
Breast Neoplasms
Cyclophosphamide augments the anti-tumor efficacy of uracil and tegafur by inhibiting dihydropyrimidine dehydrogenase.
Breast Neoplasms
Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: implication for 5-fluorouracil-based chemotherapy.
Breast Neoplasms
Dihydropyrimidine dehydrogenase activity correlates with fluorouracil sensitivity in breast cancer.
Breast Neoplasms
DPD activity and immunohistochemical DPD expression in human breast cancer.
Breast Neoplasms
Effect of dihydropyrimidine dehydrogenase single nucleotide polymorphisms on prognosis of breast cancer patients with chemotherapy.
Breast Neoplasms
Expression of the high-affinity fluoropyrimidine-preferring nucleoside transporter hCNT1 correlates with decreased disease-free survival in breast cancer.
Breast Neoplasms
Expression of thymidine phosphorylase and dihydropyrimidine dehydrogenase in human breast carcinoma cells and tissues.
Breast Neoplasms
Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer.
Breast Neoplasms
Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5-FU-based chemotherapy.
Breast Neoplasms
Prognostic significance of dihydropyrimidine dehydrogenase expression in breast cancer.
Breast Neoplasms
Severe 5-fluorouracil toxicity possibly secondary to dihydropyrimidine dehydrogenase deficiency in a breast cancer patient with osteogenesis imperfecta.
Breast Neoplasms
Successful use of uridine triacetate (Vistogard) three weeks after capecitabine in a patient with homozygous dihydropyrimidine dehydrogenase mutation: A case report and review of the literature.
Breast Neoplasms
The prognostic significance of thymidine phosphorylase, thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expressions in breast carcinomas.
Breast Neoplasms
Thymidine phosphorylase and dihydropyrimidine dehydrogenase are predictive factors of therapeutic efficacy of capecitabine monotherapy for breast cancer-preliminary results.
Breast Neoplasms
Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in breast cancer predicts 5-FU sensitivity by a histocultural drug sensitivity test.
Breast Neoplasms
[A preliminary study on dihydropyrimidine dehydrogenase activity in breast cancer]
Breast Neoplasms
[Estimation of level of enzyme induction of thymidine phosphorylase, dihydropyrimidine dehydrogenase, and thymidylate synthase in primary and recurrent breast cancer]
Breast Neoplasms
[Expressions of thymidine phosphorylase, thymidylate synthase and dihydropyrimidine dehydrogenase in breast cancer and their correlations with prognosis.]
Breast Neoplasms
[Relationships among the expression of thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase and the prognosis of breast cancer]
Breast Neoplasms
[Significance of pyrimidine nucleoside phosphorylase and dihydropyrimidine dehydrogenase levels to predict postoperative recurrence in primary breast cancer]
Breast Neoplasms
[Significance of thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) activity in breast cancer tissue]
Carcinoma
Alternative chemoradiotherapy in anal carcinoma patients with mutations in thymidylate synthase and dihydropyrimidine dehydrogenase genes.
Carcinoma
Antiproliferative effect of synthetic lignin against human breast cancer and normal fetal lung cell lines. Potency of low molecular weight fractions.
Carcinoma
CD44high/ESAlow squamous cell carcinoma cell-derived prostaglandin E2 confers resistance to 5-fluorouracil-induced apoptosis in CD44high/ESAhigh cells.
Carcinoma
Changes of gene expression of thymidine phosphorylase, thymidylate synthase, dihydropyrimidine dehydrogenase after the administration of 5'-deoxy-5-fluorouridine, paclitaxel and its combination in human gastric cancer xenografts.
Carcinoma
Characterization of dihydropyrimidine dehydrogenase on immunohistochemistry in colon carcinoma, and correlation between immunohistochemical score and protein level or messenger RNA expression.
Carcinoma
Circadian variation of dihydropyrimidine dehydrogenase mRNA expression in leukocytes and serum cortisol levels in patients with advanced gastrointestinal carcinomas compared to healthy controls.
Carcinoma
Combined Analysis of Dihydropyrimidine Dehydrogenase and Human Equilibrative Nucleoside Transporter 1 Expression Predicts Survival of Pancreatic Carcinoma Patients Treated with Adjuvant Gemcitabine Plus S-1 Chemotherapy after Surgical Resection.
Carcinoma
Comparison of 5-fluorouracil-related gene expression levels between adenocarcinomas and squamous cell carcinomas of the lung.
Carcinoma
Dihydropyrimidine dehydrogenase expression in preoperative biopsy and surgically resected specimens of gastric carcinoma.
Carcinoma
Dihydropyrimidine dehydrogenase expression predicts survival outcome and chemosensitivity to 5-fluorouracil in patients with oral squamous cell carcinoma.
Carcinoma
Effect of 5-fluorouracil and epidermal growth factor on cell growth and dihydropyrimidine dehydrogenase regulation in human uterine cervical carcinoma SKG-IIIb cells.
Carcinoma
Effects of combined administration of DPD-inhibitory oral fluoropyrimidine, S-1, plus paclitaxel on gene expressions of fluoropyrimidine metabolism-related enzymes in human gastric xenografts.
Carcinoma
Effects of smoking and alcohol consumption on 5-fluorouracil-related metabolic enzymes in oral squamous cell carcinoma.
Carcinoma
Evaluation of TS-1 based treatment and expression of thymidylate synthase and dihydropyrimidine dehydrogenase on oral squamous cell carcinoma.
Carcinoma
Expression levels of thymidylate synthase, thymidylate phosphorylase and dihydropyrimidine dehydrogenase in head and neck squamous cell carcinoma: preliminary study.
Carcinoma
Expression of dihydropyrimidine dehydrogenase in cancer cells but not in stromal cells predicts the efficacy of fluorouracil treatment in patients with gastric carcinoma.
Carcinoma
Expression of thymidylate synthase and dihydropyrimidine dehydrogenase in adenoid cystic carcinoma of the head and neck: correlation with clinical outcome.
Carcinoma
Expression of thymidylate synthase and dihydropyrimidine dehydrogenase in oral squamous cell carcinoma: possible markers as predictors of clinical outcome.
Carcinoma
Expression of thymidylate synthase and dihydropyrimidine dehydrogenase in primary oral squamous cell carcinoma and corresponding metastases in cervical lymph nodes: association with the metastasis suppressor CD82.
Carcinoma
High expression of thymidylate synthase leads to resistance to 5-fluorouracil in biliary tract carcinoma in vitro.
Carcinoma
Human equilibrative nucleoside transporter 1, as a predictor of 5-fluorouracil resistance in human pancreatic cancer.
Carcinoma
Impact of intratumoral thymidylate synthase expression on prognosis after surgical resection for ampullary carcinoma.
Carcinoma
Levels and expressions of orotate phosphoribosyltransferase in gastric carcinoma and normal gastric mucosa tissues.
Carcinoma
Novel 5-fluorouracil-resistant human esophageal squamous cell carcinoma cells with dihydropyrimidine dehydrogenase overexpression.
Carcinoma
Orotate phosphoribosyl transferase mRNA expression in oral squamous cell carcinoma and its relationship with the dihydropyrimidine dehydrogenase expression and the clinical effect of 5-fluorouracil.
Carcinoma
Preoperative radiotherapy and concomitant capecitabine treatment induce thymidylate synthase and thymidine phosphorylase mRNAs in rectal carcinoma.
Carcinoma
Prognostic significance of 5-fluorouracil metabolism-relating enzymes and enhanced chemosensitivity to 5-fluorouracil by 5-chloro 2,4-dihydroxy-pyridine in urothelial carcinoma.
Carcinoma
Prognostic Value of Excision Repair Cross-Complementing Gene 1, Dihydropyrimidine Dehydrogenase, and Human Equilibrative Nucleotide Transporter 1 Expression and Their Implications for Adjuvant Treatment in Patients With Ampullary Carcinoma.
Carcinoma
Quantitative analysis of thymidine phosphorylase and dihydropyrimidine dehydrogenase in renal cell carcinoma.
Carcinoma
Relationship between protein levels and gene expression of dihydropyrimidine dehydrogenase in human tumor cells during growth in culture and in nude mice.
Carcinoma
Role of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expressions in gallbladder carcinoma.
Carcinoma
Significance of dihydropyrimidine dehydrogenase activity in renal cell carcinoma.
Carcinoma
Study of Thymidylate Synthase (TS) and Dihydropyrimidine Dehydrogenase (DPD) Expressions on 5-Fluorouracil in Oral Squamous Cell Carcinoma
Carcinoma
The effect of neoadjuvant therapy on the 5-fluorouracil metabolic and relative enzymes of oral squamous cell carcinoma.
Carcinoma
The predictive and therapeutic value of thymidine phosphorylase and dihydropyrimidine dehydrogenase in capecitabine (Xeloda)-based chemotherapy for head and neck cancer.
Carcinoma
The role of dihydropyrimidine dehydrogenase expression in resistance to 5-fluorouracil in head and neck squamous cell carcinoma cells.
Carcinoma
Thymidine phosphorylase and dihydropyrimidine dehydrogenase in renal cell carcinoma: relationship between histological parameters and chemosensitivity to 5-fluorouracil.
Carcinoma
Thymidylate synthase and dihydropyrimidine dehydrogenase expression in oral squamous cell carcinoma: an immunohistochemical and clinicopathologic study.
Carcinoma
Thymidylate synthase and dihydropyrimidine dehydrogenase expressions in gallbladder cancer.
Carcinoma
Thymidylate synthetase (TS) genotype and TS/dihydropyrimidine dehydrogenase mRNA level as an indicator in determining chemosensitivity to 5-fluorouracil in advanced gastric carcinoma.
Carcinoma
Thymidylate synthetase and dihydropyrimidine dehydrogenase mRNA levels in esophageal cancer.
Carcinoma
Where should the specimen be excised for the chemosensitivity of colorectal cancer to 5-fluorouracil?
Carcinoma
[Assessment of dihydropyrimidine dehydrogenase and thymidylate synthase expression in gastric carcinoma and colonic carcinoma]
Carcinoma
[Four resected cases with basaloid carcinoma of esophagus--comparison of 5-FU-related enzymes (thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), orotate phosphoribosyl transferase (OPRT)) between basaloid carcinoma and squamous cell carcinoma].
Carcinoma
[Orotate phosphoribosyltransferase levels in gastric carcinoma and normal gastric mucosa - correlation with thymidylate synthase and dihydropyrimidine dehydrogenase levels and the changes after neoadjuvant chemotherapy.]
Carcinoma
[The association between DPYD gene polymorphism and chemotherapeutic toxicity of 5-FU in gastric carcinoma and colonic carcinoma]
Carcinoma, Adenoid Cystic
Expression of thymidylate synthase and dihydropyrimidine dehydrogenase in adenoid cystic carcinoma of the head and neck: correlation with clinical outcome.
Carcinoma, Hepatocellular
A novel immunotherapeutic modality with direct hemoperfusion targeting transforming growth factor-beta prolongs the survival of tumor-bearing rats.
Carcinoma, Hepatocellular
Alteration of dihydropyrimidine dehydrogenase expression by IFN-alpha affects the antiproliferative effects of 5-fluorouracil in human hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Clinical significance of the thymidylate synthase, dihydropyrimidine dehydrogenase, and thymidine phosphorylase mRNA expressions in hepatocellular carcinoma patients receiving 5-fluorouracil-based transarterial chemoembolization treatment.
Carcinoma, Hepatocellular
Combination chemotherapy with S-1 and platinum in advanced hepatocellular carcinoma.
Carcinoma, Hepatocellular
Consensus interferon enhances the anti-proliferative effect of 5-fluorouracil on human hepatoma cells via downregulation of dihydropyrimidine dehydrogenase expression.
Carcinoma, Hepatocellular
Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma: implication in 5-fluorouracil-based chemotherapy.
Carcinoma, Hepatocellular
Dihydropyrimidine dehydrogenase and thymidylate synthase activities in hepatocellular carcinomas and in diseased livers.
Carcinoma, Hepatocellular
Dihydropyrimidine dehydrogenase predicts survival and response to interferon-? in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Elevated levels of mRNAs encoding dihydropyrimidine dehydrogenase and thymidylate synthase are associated with improved survival of patients with hepatocellular carcinoma treated with S-1.
Carcinoma, Hepatocellular
Oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma.
Carcinoma, Hepatocellular
Possible involvement of glutathione balance disruption in dihydropyrazine-induced cytotoxicity on human hepatoma HepG2 cells.
Carcinoma, Hepatocellular
Significance of dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expressions in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1.
Carcinoma, Hepatocellular
Thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in hepatocellular carcinoma and metastatic liver cancer.
Carcinoma, Hepatocellular
[Anti-tumor effects of various interferons-alpha +5-fluorouracil via downregulation of dihydropyrimidine dehydrogenase in hepatoma cells]
Carcinoma, Non-Small-Cell Lung
A feasibility study of postoperative adjuvant chemotherapy with fluoropyrimidine S-1 in patients with stage II-IIIA non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Feasibility study of postoperative adjuvant chemotherapy with S-1 (tegaful, gimeracil, oteracil potassium) for non-small cell lung cancer-LOGIK 0601 study.
Carcinoma, Non-Small-Cell Lung
Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5-FU-based chemotherapy.
Carcinoma, Non-Small-Cell Lung
Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (tegafur+uracil) in patients with non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Synergistic antitumor activity of the SN-38-incorporating polymeric micelles NK012 with S-1 in a mouse model of Non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Thymidine phosphorylase levels and dihydropyrimidine dehydrogenase levels in non-small cell lung cancer tissues.
Carcinoma, Non-Small-Cell Lung
Thymidylate synthase and dihydropyrimidine dehydrogenase activities in non-small cell lung cancer tissues: relationship with in vitro sensitivity to 5-fluorouracil.
Carcinoma, Non-Small-Cell Lung
Thymidylate synthase and dihydropyrimidine dehydrogenase expression levels are associated with response to S-1 plus carboplatin in advanced non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer: relationship between mRNA expression and activity.
Carcinoma, Non-Small-Cell Lung
Thymidylate synthase expression is closely associated with outcome in patients with pulmonary adenocarcinoma.
Carcinoma, Ovarian Epithelial
Gene expression for dihydropyrimidine dehydrogenase and thymidine phosphorylase influences outcome in epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
Relationship between the expression of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase and survival in epithelial ovarian cancer.
Carcinoma, Renal Cell
Quantitative analysis of thymidine phosphorylase and dihydropyrimidine dehydrogenase in renal cell carcinoma.
Carcinoma, Renal Cell
Significance of dihydropyrimidine dehydrogenase activity in renal cell carcinoma.
Carcinoma, Renal Cell
Thymidine phosphorylase and dihydropyrimidine dehydrogenase in renal cell carcinoma: relationship between histological parameters and chemosensitivity to 5-fluorouracil.
Carcinoma, Squamous Cell
CD44high/ESAlow squamous cell carcinoma cell-derived prostaglandin E2 confers resistance to 5-fluorouracil-induced apoptosis in CD44high/ESAhigh cells.
Carcinoma, Squamous Cell
Comparison of 5-fluorouracil-related gene expression levels between adenocarcinomas and squamous cell carcinomas of the lung.
Carcinoma, Squamous Cell
Expression levels of thymidylate synthase, thymidylate phosphorylase and dihydropyrimidine dehydrogenase in head and neck squamous cell carcinoma: preliminary study.
Carcinoma, Squamous Cell
The predictive and therapeutic value of thymidine phosphorylase and dihydropyrimidine dehydrogenase in capecitabine (Xeloda)-based chemotherapy for head and neck cancer.
Carcinoma, Squamous Cell
The role of dihydropyrimidine dehydrogenase expression in resistance to 5-fluorouracil in head and neck squamous cell carcinoma cells.
Carcinoma, Transitional Cell
Thymidine phosphorylase and dihydropyrimidine dehydrogenase in bladder cancer.
Cardiomegaly
Integration of network pharmacology and molecular docking technology reveals the mechanism of the herbal pairing of Codonopsis Pilosula (Franch.) Nannf and Astragalus Membranaceus (Fisch.) Bge on chronic heart failure.
Cardiomegaly
[Effects of m-Nif and Nif on left ventricle hypertrophy in rats induced by partial ligation of abdominal aorta]
Cardiomyopathies
Isradipine prevents the development of spontaneously occurring cardiac necrosis in cardiomyopathic hamster.
Cardiomyopathy, Dilated
Uniformity of calcium channel number and isometric contraction in human right and left ventricular myocardium.
Cardiotoxicity
Cardiotoxicity of 5-fluorouracil and capecitabine in a pancreatic cancer patient with a novel mutation in the dihydropyrimidine dehydrogenase gene.
Cardiotoxicity
Do local anaesthetics interact with dihydropyridine binding sites on neuronal L-type Ca2+ channels?
Cardiovascular Diseases
A simple and fast LC-MS/MS method with a very high sensitivity for the measurement of raltitrexed in human plasma.
Cardiovascular Diseases
Construction of a high-affinity receptor site for dihydropyridine agonists and antagonists by single amino acid substitutions in a non-L-type Ca2+ channel.
Cardiovascular Diseases
Pharmacology of N-type Ca2+ channels distributed in cardiovascular system (Review).
Cardiovascular Diseases
The influence of cardiovascular disease on quality of life in type 2 diabetics.
Cardiovascular Diseases
Unique atheroprotective property of azelnidipine, a dihydropyridine-based calcium antagonist.
Cholangiocarcinoma
Role of dihydropyrimidine dehydrogenase and thymidylate synthase expression in immunohistochemistry of intrahepatic cholangiocarcinoma.
Cholangiocarcinoma
Role of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA in intrahepatic cholangiocarcinoma.
Colonic Neoplasms
ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer.
Colonic Neoplasms
Changes over time in thymidine phosphorylase and dihydropyrimidine dehydrogenase when colon cancer samples are left at room temperature.
Colonic Neoplasms
Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients.
Colonic Neoplasms
Efficacy of laser capture microdissection plus RT-PCR technique in analyzing gene expression levels in human gastric cancer and colon cancer.
Colonic Neoplasms
Erratum: Publisher Correction to: Severe adverse events due to dihydropyrimidine dehydrogenase deficiency in a Japanese patient with colon cancer taking capecitabine: a case report.
Colonic Neoplasms
Genetic polymorphisms of dihydropyrimidinase in a Japanese patient with capecitabine-induced toxicity.
Colonic Neoplasms
Logistic regression model of the clinical response to 5-fluorouracil based chemotherapy for metastatic colorectal cancer patients.
Colonic Neoplasms
Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly treated stage III colon cancer patients.
Colonic Neoplasms
Protein-bound polysaccharide-K augments the anticancer effect of fluoropyrimidine derivatives possibly by lowering dihydropyrimidine dehydrogenase expression in gastrointestinal cancers.
Colonic Neoplasms
Pyrimidine nucleoside phosphorylase and dihydropyrimidine dehydrogenase indicate chemosensitivity of human colon cancer specimens to doxifluridine and 5-fluorouracil, respectively.
Colonic Neoplasms
Regulation of genes of the circadian clock in human colon cancer: reduced period-1 and dihydropyrimidine dehydrogenase transcription correlates in high-grade tumors.
Colonic Neoplasms
Severe adverse events due to dihydropyrimidine dehydrogenase deficiency in a Japanese patient with colon cancer taking capecitabine: a case report.
Colonic Neoplasms
Significance of expression of pyrimidine metabolizing genes in colon cancer.
Colonic Neoplasms
Thymidilate synthase expression predicts longer survival in patients with stage II colon cancer treated with 5-flurouracil independently of microsatellite instability.
Colonic Neoplasms
[Analysis of the salvage synthesis within biosynthesis of nucleic acid route in colon cancer]
Colonic Neoplasms
[Dihydropyrimidine dehydrogenase and thymidylate synthase activities in colonic cancer tissue and sensitivity to 5-fluorouracil]
Colonic Neoplasms
[Significance of thymidylate synthase and dihydropyrimidine dehydrogenase activity in colon cancer]
Colorectal Neoplasms
5-Fluorouracil toxicity-attributable IVS14 + 1G > A mutation of the dihydropyrimidine dehydrogenase gene in Polish colorectal cancer patients.
Colorectal Neoplasms
5-Fluorouracil-related gene expression in hepatic artery infusion-treated patients with hepatic metastases from colorectal carcinomas.
Colorectal Neoplasms
5-Fluorouracil-related gene expression in primary sites and hepatic metastases of colorectal carcinomas.
Colorectal Neoplasms
A predictive biomarker for altered 5-fluorouracil pharmacokinetics following repeated administration in a rat model of colorectal cancer.
Colorectal Neoplasms
Analysis of the mRNA Expression Levels of Thymidylate Synthase (TS), Dihydropyrimidine Dehydrogenase (DPD) and Orotate Phosphoribosyl Transferase (OPRT) in Liver Metastases from Colorectal Cancer.
Colorectal Neoplasms
ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer.
Colorectal Neoplasms
Association of time to recurrence with thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression in stage II and III colorectal cancer.
Colorectal Neoplasms
Biochemical modulation of 5-fluorouacil through dihydropyrimidine dehydrogenase inhibition: a Southwest Oncology Group phase II trial of eniluracil and 5-fluorouracil in advanced resistant colorectal cancer.
Colorectal Neoplasms
Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer.
Colorectal Neoplasms
Characterization of dihydropyrimidine dehydrogenase in human colorectal tumours.
Colorectal Neoplasms
Clinical implications of thymidylate synthetase, dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase activity levels in colorectal carcinoma following radical resection and administration of adjuvant 5-FU chemotherapy.
Colorectal Neoplasms
Clinical relevance of the concentrations of both pyrimidine nucleoside phosphorylase (PyNPase) and dihydropyrimidine dehydrogenase (DPD) in colorectal cancer.
Colorectal Neoplasms
Clinical role of orotate phosphoribosyl transferase and dihydropyrimidine dehydrogenase in colorectal cancer treated with postoperative fluoropyrimidine.
Colorectal Neoplasms
Clinical role of thymidine phosphorylase and dihydropyrimidine dehydrogenase in colorectal cancer treated with postoperative fluoropyrimidine.
Colorectal Neoplasms
Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase.
Colorectal Neoplasms
Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer.
Colorectal Neoplasms
Comparative analysis of thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in gastric and colorectal cancers.
Colorectal Neoplasms
Comparative analysis of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in colorectal cancer and surrounding normal tissue.
Colorectal Neoplasms
Correlation between chemosensitivity and mRNA expression level of 5-fluorouracil-related metabolic enzymes during liver metastasis of colorectal cancer.
Colorectal Neoplasms
Correlations between expression levels of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase, and efficacy of 5-fluorouracil-based chemotherapy for advanced colorectal cancer.
Colorectal Neoplasms
Correlations of Clinicopathological Factors with Protein Expression Levels of Thymidylate Synthase, Dihydropyrimidine Dehydrogenase and Orotate Phosphoribosyltransferase in Colorectal Cancer.
Colorectal Neoplasms
Cost Implications of Reactive Versus Prospective Testing for Dihydropyrimidine Dehydrogenase Deficiency in Patients With Colorectal Cancer: A Single-Institution Experience.
Colorectal Neoplasms
Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance.
Colorectal Neoplasms
Design and evaluation of colon targeted modified pulsincap delivery of 5-fluorouracil according to circadian rhythm.
Colorectal Neoplasms
Differences in dihydropyrimidine dehydrogenase activities between gastric and colorectal cancer.
Colorectal Neoplasms
Dihydropyrimidine dehydrogenase (DPD) rapidly regenerates after inactivation by eniluracil (GW776C85) in primary and metastatic colorectal cancer.
Colorectal Neoplasms
Dihydropyrimidine dehydrogenase activity and thymidylate synthase level are associated with response to 5-fluorouracil in human colorectal cancer.
Colorectal Neoplasms
Dihydropyrimidine Dehydrogenase Activity during Long-Term Adjuvant Treatment with Oral Uracil and Tegafur for Colorectal Cancer.
Colorectal Neoplasms
Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in colorectal cancer.
Colorectal Neoplasms
Dihydropyrimidine dehydrogenase but not thymidylate synthase expression is associated with resistance to 5-fluorouracil in colorectal cancer.
Colorectal Neoplasms
Dihydropyrimidine dehydrogenase inhibition as a strategy for the oral administration of 5-fluorouracil: utility in the treatment of advanced colorectal cancer.
Colorectal Neoplasms
Dihydropyrimidine Dehydrogenase Levels in Colorectal Cancer Cells Treated with a Combination of Heat Shock Protein 90 Inhibitor and Oxaliplatin or Capecitabine.
Colorectal Neoplasms
Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer.
Colorectal Neoplasms
DPYD, TYMS and MTHFR Genes Polymorphism Frequencies in a Series of Turkish Colorectal Cancer Patients.
Colorectal Neoplasms
Enhanced 5-fluorouracil cytotoxicity in high cyclooxygenase-2 expressing colorectal cancer cells and xenografts induced by non-steroidal anti-inflammatory drugs via downregulation of dihydropyrimidine dehydrogenase.
Colorectal Neoplasms
Eniluracil treatment completely inactivates dihydropyrimidine dehydrogenase in colorectal tumors.
Colorectal Neoplasms
Evaluation of clinical value of single nucleotide polymorphisms of dihydropyrimidine dehydrogenase gene to predict 5-Fluorouracil toxicity in 60 colorectal cancer patients in China.
Colorectal Neoplasms
Expression level of thymidylate synthase is a good predictor of chemosensitivity to 5-fluorouracil in colorectal cancer.
Colorectal Neoplasms
Expression level of thymidylate synthase mRNA reflects 5-fluorouracil sensitivity with low dose and long duration in primary colorectal cancer.
Colorectal Neoplasms
Expression levels of thymidylate synthase, dihydropyrimidine dehydrogenase, and thymidine phosphorylase in patients with colorectal cancer.
Colorectal Neoplasms
Expression of dihydropyrimidine dehydrogenase, orotate phosphoribosyl transferase and thymidylate synthase in patients with primary colorectal cancer, and associations with site of first metastasis.
Colorectal Neoplasms
Expression of dihydropyrimidine dehydrogenase, thymidylate synthase, p53 and p21 in metastatic liver tumor from colorectal cancer after 5-fluorouracil-based chemotherapy.
Colorectal Neoplasms
Feasibility of Integrating Panel-Based Pharmacogenomics Testing for Chemotherapy and Supportive Care in Patients With Colorectal Cancer.
Colorectal Neoplasms
Fluoropyrimidine-induced toxicity and DPD deficiency.. A case report of early onset, lethal capecitabine-induced toxicity and mini review of the literature. Uridine triacetate: Efficacy and safety as an antidote. Is it accessible outside USA?
Colorectal Neoplasms
Gender differences in the dihydropyrimidine dehydrogenase expression of colorectal cancers.
Colorectal Neoplasms
Gene expression of 5-fluorouracil metabolic enzymes in primary colorectal cancer and corresponding liver metastasis.
Colorectal Neoplasms
High-resolution melting analysis of the common c.1905+1G>A mutation causing dihydropyrimidine dehydrogenase deficiency and lethal 5-fluorouracil toxicity.
Colorectal Neoplasms
Identification of a novel mutation in the dihydropyrimidine dehydrogenase gene in a patient with a lethal outcome following 5-fluorouracil administration and the determination of its frequency in a population of 500 patients with colorectal carcinoma.
Colorectal Neoplasms
Immunohistochemical dihydropyrimidine dehydrogenase expression is a good prognostic indicator for patients with Dukes' C colorectal cancer.
Colorectal Neoplasms
Impact of SHMT1 polymorphism on the clinical outcome of patients with metastatic colorectal cancer treated with first-line FOLFIRI+bevacizumab.
Colorectal Neoplasms
Influence of DPYD Genetic Polymorphisms on 5-Fluorouracil Toxicities in Patients with Colorectal Cancer: A Meta-Analysis.
Colorectal Neoplasms
Intratumoral dihydropyrimidine dehydrogenase messenger RNA level reflects tumor progression in human colorectal cancer.
Colorectal Neoplasms
Intratumoural thymidylate synthase and dihydropyrimidine dehydrogenase activities are good predictors of 5-fluorouracil sensitivity in colorectal cancer.
Colorectal Neoplasms
Methylenetetrahydrofolate reductase C677T is not associated with expression of pyrimidine metabolic enzyme genes in colorectal cancer.
Colorectal Neoplasms
Microsatellite instability in colorectal cancer and association with thymidylate synthase and dihydropyrimidine dehydrogenase expression.
Colorectal Neoplasms
Modified Irinotecan/5FU/Leucovorin therapy in advanced colorectal cancer and predicting therapeutic efficacy by expression of tumor-related enzymes.
Colorectal Neoplasms
Mutations in exon 14 of dihydropyrimidine dehydrogenase and 5-Fluorouracil toxicity in Portuguese colorectal cancer patients.
Colorectal Neoplasms
Overcoming acquired drug resistance in colorectal cancer cells by targeted delivery of 5-FU with EGF grafted hollow mesoporous silica nanoparticles.
Colorectal Neoplasms
Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy.
Colorectal Neoplasms
Pharmacogenomics in colorectal carcinomas: future perspectives in personalized therapy.
Colorectal Neoplasms
Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications.
Colorectal Neoplasms
Pharmacokinetic/pharmacodynamic modeling of 5-fluorouracil by using a biomarker to predict tumor growth in a rat model of colorectal cancer.
Colorectal Neoplasms
Pharmacokinetics of 5-fluorouracil and increased hepatic dihydropyrimidine dehydrogenase activity levels in 1,2-dimethylhydrazine-induced colorectal cancer model rats.
Colorectal Neoplasms
Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group.
Colorectal Neoplasms
Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase.
Colorectal Neoplasms
Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer.
Colorectal Neoplasms
Potential of dihydropyrimidine dehydrogenase genotypes in personalizing 5-Fluorouracil therapy among colorectal cancer patients.
Colorectal Neoplasms
Pre-therapeutic assessment of plasma dihydrouracil/uracil ratio for predicting the pharmacokinetic parameters of 5-fluorouracil and tumor growth in a rat model of colorectal cancer.
Colorectal Neoplasms
Predicting 5-fluorouracil chemosensitivity of liver metastases from colorectal cancer using primary tumor specimens: three-gene expression model predicts clinical response.
Colorectal Neoplasms
Predicting 5-FU sensitivity using human colorectal cancer specimens: comparison of tumor dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase activities with in vitro chemosensitivity to 5-FU.
Colorectal Neoplasms
Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: A systemic review of current development, evidence, and recommendation.
Colorectal Neoplasms
Predictive diagnostics in colorectal cancer: impact of genetic polymorphisms on individual outcomes and treatment with fluoropyrimidine-based chemotherapy.
Colorectal Neoplasms
Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Colorectal Neoplasms
Prognostic effects of dihydropyrimidine dehydrogenase in advanced colorectal cancer after surgery: immunohistochemistry using a new monoclonal antibody.
Colorectal Neoplasms
Prognostic impact of orotate phosphoribosyl transferase among 5-fluorouracil metabolic enzymes in resectable colorectal cancers treated by oral 5-fluorouracil-based adjuvant chemotherapy.
Colorectal Neoplasms
Prognostic markers in early-stage colorectal cancer: significance of TYMS mRNA expression.
Colorectal Neoplasms
Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy.
Colorectal Neoplasms
Putative role of dihydropyrimidine dehydrogenase in the toxic side effect of 5-fluorouracil in colorectal cancer patients.
Colorectal Neoplasms
Quantitation of dihydropyrimidine dehydrogenase (DPD) mRNA expression levels in normal colon and colorectal cancer tumor paraffin-embedded tissue specimens.
Colorectal Neoplasms
Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
Colorectal Neoplasms
Real-time RT-PCR (TaqMan) of tumor mRNA to predict sensitivity of specimens to 5-fluorouracil.
Colorectal Neoplasms
Recommendation on testing for dihydropyrimidine dehydrogenase deficiency in the ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.
Colorectal Neoplasms
Regional and systemic therapies for advanced colorectal carcinoma: randomized clinical trial results.
Colorectal Neoplasms
Relationship between intratumoral dihydropyrimidine dehydrogenase activity and gene expression in human colorectal cancer.
Colorectal Neoplasms
Relationship between plasma concentrations of 5-fluorouracil and 5-fluoro-5,6-dihydrouracil and toxicity of 5-fluorouracil infusions in cancer patients.
Colorectal Neoplasms
Relationships between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase and cell proliferative activity and 5-fluorouracil sensitivity in colorectal carcinoma.
Colorectal Neoplasms
Response to Letter: Cost Implications of Reactive Versus Prospective Testing for Dihydropyrimidine Dehydrogenase Deficiency in Patients With Colorectal Cancer: A Single-Institution Experience.
Colorectal Neoplasms
S-1 plus Raltitrexed for Refractory Metastatic Colorectal Cancer: A Phase II Trial.
Colorectal Neoplasms
SphK2 confers 5-fluorouracil resistance to colorectal cancer via upregulating H3K56ac-mediated DPD expression.
Colorectal Neoplasms
Tegafur-uracil (UFT) in lower doses is safe for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle.
Colorectal Neoplasms
Tegafur-uracil is a safe alternative for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle.
Colorectal Neoplasms
The activities of thymidine phosphorylase and dihydropyrimidine dehydrogenase in colorectal cancer depend on where the sample is taken.
Colorectal Neoplasms
The dihydrouracil/uracil ratio in plasma, clinical and genetic analysis for screening of dihydropyrimidine dehydrogenase deficiency in colorectal cancer patients treated with 5-fluorouracil.
Colorectal Neoplasms
The dihydrouracil/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients.
Colorectal Neoplasms
The expression profiles of orotate phosphoribosyltransferase and dihydropyrimidine dehydrogenase in gastric cancer and their clinical significance.
Colorectal Neoplasms
The prognostic significance of thymidylate synthase and dihydropyrimidine dehydrogenase in colorectal cancer of 303 patients adjuvantly treated with 5-fluorouracil.
Colorectal Neoplasms
The relationship between survival and the expression of dihydropyrimidine dehydrogenase in patients with colorectal cancer.
Colorectal Neoplasms
The role of IVS14+1 G > A genotype detection in the dihydropyrimidine dehydrogenase gene and pharmacokinetic monitoring of 5-fluorouracil in the individualized adjustment of 5-fluorouracil for patients with local advanced and metastatic colorectal cancer: a preliminary report.
Colorectal Neoplasms
The role of oxaliplatin in the treatment of advanced metastatic colorectal cancer: prospects and future directions.
Colorectal Neoplasms
The SOFT trial: a Phase III study of the dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 and oxaliplatin (SOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer.
Colorectal Neoplasms
The stability of dihydropyrimidine dehydrogenase activity in colorectal cancer tissue after resection.
Colorectal Neoplasms
Thymidine phosphorylase and dihydropyrimidine dehydrogenase activity in colorectal carcinoma and patients prognosis.
Colorectal Neoplasms
Thymidine phosphorylase and dihydropyrimidine dehydrogenase expression levels in tumor and normal tissue specimens of t3 human colorectal carcinoma.
Colorectal Neoplasms
Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5'-deoxy-5-fluorouridine as adjuvant chemotherapy.
Colorectal Neoplasms
Thymidine phosphorylase and dihydropyrimidine dehydrogenase protein expression in colorectal cancer.
Colorectal Neoplasms
Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer.
Colorectal Neoplasms
Thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expression in primary colorectal tumors-correlation to tumor histopathology and clinical follow-up.
Colorectal Neoplasms
Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression after administration of 5-fluorouracil to patients with colorectal cancer.
Colorectal Neoplasms
Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Colorectal Neoplasms
Thymidylate synthase and thymidine phosphorylase mRNA expression in primary lesions using laser capture microdissection is useful for prediction of the efficacy of FOLFOX treatment in colorectal cancer patients with liver metastasis.
Colorectal Neoplasms
Thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer and normal mucosa in patients.
Colorectal Neoplasms
Tumor dihydropyrimidine dehydrogenase expression is a useful marker in adjuvant therapy with oral fluoropyrimidines after curative resection of colorectal cancer.
Colorectal Neoplasms
Tumor dihydropyrimidine dehydrogenase in stage II and III colorectal cancer: low level expression is a beneficial marker in oral-adjuvant chemotherapy, but is also a predictor for poor prognosis in patients treated with curative surgery alone.
Colorectal Neoplasms
Upregulation of enzymes metabolizing 5-fluorouracil in colorectal cancer.
Colorectal Neoplasms
Value of plasma SN-38 levels and DPD activity in irinotecan-based individualized chemotherapy for advanced colorectal cancer with heterozygous type UGT1A1*6 or UGT1A1*28.
Colorectal Neoplasms
Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients.
Colorectal Neoplasms
[Activities of thymidylate synthase and dihydropyrimidine dehydrogenase in patients with colorectal cancer]
Colorectal Neoplasms
[Clinical significance of determinations of dihydropyrimidine dehydrogenase levels in primary and hepatic lesions of colorectal cancer patients]
Colorectal Neoplasms
[Clinicopathological significance of pyrimidine nucleoside phosphorylase (PyNPase) and dihydropyrimidine dehydrogenase (DPD) in advanced colorectal cancer]
Colorectal Neoplasms
[Correlation between 5-fluorouracil (5-FU) sensitivity as measured by collagen gel droplet embedded culture drug sensitivity test (CD-DST) and expression of orotate phosphoribosyl transferase (OPRT), thymidylate synthase (TS), and dihydropyrimidine dehydrogenase (DPD) in colorectal cancer]
Colorectal Neoplasms
[Correlation between clinical pathologic factors and enzymatic activity of orotate Phosphoribosyl transferase (OPRT), Dihydropyrimidine dehydrogenase (DPD) and Thymidylate synthase (TS) in colorectal cancer]
Colorectal Neoplasms
[Correlation between clinical pathophysiologic factors and expression of orotate phosphoribosyl transferase (OPRT), thymidylate synthase (TS), and dihydropyrimidine dehydrogenase (DPD) in colorectal cancer]
Colorectal Neoplasms
[Determination of dihydropyrimidine dehydrogenase in the prediction of toxic side effects of 5-fluorouracil]
Colorectal Neoplasms
[Dihydropyrimidine dehydrogenase gene expression in patients with hepatic metastases from colorectal cancer]
Colorectal Neoplasms
[Effect of peroral doxifluridine plus hepatic arterial infusion for synchronous liver metastasis of colorectal cancer--correlation with the expression of thymidine phosphorylase and dihydropyrimidine dehydrogenase in primary colorectal cancer lesions]
Colorectal Neoplasms
[Expression of dihydropyrimidine dehydrogenase in human colorectal carcinoma and its clinical implications]
Colorectal Neoplasms
[Expression of dihydropyrimidine dehydrogenase in primary colorectal cancer and liver metastasis--a relationship between mRNA levels in cancer cells and protein levels in cancerous tissue and effect of 5-fluorouracil]
Colorectal Neoplasms
[Expression of mRNA levels of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase of colorectal cancer--relationships among mRNA levels in association with response to 5-FU based treatment]
Colorectal Neoplasms
[Expression of mRNA levels of thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase and orotate phosphoribosyltransferase in diffusely infiltrating colorectal cancer]
Colorectal Neoplasms
[Hepatic recurrence after prophylactic hepatic arterial infusion of 5-fluorouracil for Dukes' C colorectal cancer--correlation with the expression of dihydropyrimidine dehydrogenase in the primary tumor]
Colorectal Neoplasms
[Relationship of serum level of dihydropyrimidine dehydrogenase and serum concentration of 5-fluorouracil to treatment response and adverse events in colorectal cancer patients]
Colorectal Neoplasms
[Results of prophylactic hepatic arterial chemotherapy for liver metastases of Dukes C colorectal cancer--correlation with tumoral expression of dihydropyrimidine dehydrogenase, thymidylate synthase, p53, or orotate phosphoribosyl transferase]
Colorectal Neoplasms
[The Relationship between the efficacy of mFOLFOX6 treatment and the expression of TS, DPD, TP, and ERCC-1 in unresectable colorectal cancer].
Colorectal Neoplasms
[Thymidylate synthase and dihydropyrimidine dehydrogenase activity in a metastatic liver tumor from colorectal cancer]
Colorectal Neoplasms
[Thymidylate synthase and dihydropyrimidine dehydrogenase gene expressions in colorectal cancer using the Danenberg tumor profile method]
Colorectal Neoplasms
[Tumoral dihydropyrimidine dehydrogenase expression and efficacy of 5-fluorouracil plus leucovorin plus UFT therapy in patients with colorectal cancer]
Colorectal Neoplasms
[Tumoral levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in elderly colorectal cancer patients]
Coma
Novel index for predicting mortality during the first 24 hours after traumatic brain injury.
Coma
Successful treatment by direct hemoperfusion of coma possibly resulting from mitochondrial dysfunction in acute valproate intoxication.
Communicable Diseases
Endotoxin removal column containing polymyxin B immobilized fiber is useful for the treatment of the patient with Vibrio vulnificus septicemia.
Coronary Artery Disease
[Influence of cardiovascular risk factors on prescribing of antihypertensives]
Coronary Disease
Effects of amlodipine on coronary hemodynamics and vascular responses to sympathetic stimulation in patients with coronary heart disease.
COVID-19
Risk for dental healthcare professionals during the COVID-19 global pandemic: An evidence-based assessment.
Decompression Sickness
Mechanistic insights revealed by the crystal structure of a histidine kinase with signal transducer and sensor domains.
Delirium
Is Health-Related Quality of Life an Independent Prognostic Factor For 12-Month Mortality and Nursing Home Placement among Elderly Patients Hospitalized via the Emergency Department?
Dementia
Is Health-Related Quality of Life an Independent Prognostic Factor For 12-Month Mortality and Nursing Home Placement among Elderly Patients Hospitalized via the Emergency Department?
Diabetes Complications
Dihydroprogesterone Increases the Gene Expression of Myelin Basic Protein in Spinal Cord of Diabetic Rats.
Diabetes Complications
The validity and reliability of the Diabetes Health Profile (DHP) in NIDDM patients referred for insulin therapy.
Diabetes Mellitus
Peripheral blood mononuclear cell dihydropyrimidine dehydrogenase activity in volunteers with and without diabetes mellitus.
Diabetes Mellitus, Type 1
Patient-assessed health outcome measures for diabetes: a structured review.
Diabetes Mellitus, Type 2
Adaptation of the Diabetes Health Profile (DHP-1) for use with patients with Type 2 diabetes mellitus: psychometric evaluation and cross-cultural comparison.
Diabetes Mellitus, Type 2
The validity and reliability of the Diabetes Health Profile (DHP) in NIDDM patients referred for insulin therapy.
Diabetic Neuropathies
Progesterone and its derivatives are neuroprotective agents in experimental diabetic neuropathy: a multimodal analysis.
dihydropyrimidinase deficiency
5-Fluorouracil rechallenge after 5-fluorouracil-induced hyperammonemic encephalopathy.
dihydropyrimidinase deficiency
5-Fluorouracil-induced hyperammonaemic encephalopathy: A French national survey.
dihydropyrimidinase deficiency
5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency.
dihydropyrimidinase deficiency
5-FU multifocal inflammatory leukoencephalopathy and dihydropyrimidine dehydrogenase deficiency.
dihydropyrimidinase deficiency
A bilateral cicatricial ectropion and bilateral upper lid shortening caused by 5-fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency.
dihydropyrimidinase deficiency
A case of dihydropyrimidinase deficiency incidentally detected by urine metabolome analysis.
dihydropyrimidinase deficiency
A case of necrotic enteritis during neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic ductal adenocarcinoma.
dihydropyrimidinase deficiency
A comprehensive population-based study comparing the phenotype and genotype in a pretherapeutic screen of dihydropyrimidine dehydrogenase deficiency.
dihydropyrimidinase deficiency
A Facile Method for the Quantification of Urinary Uracil Concentration by a Uracil-Specific Fluorescence Derivatization Reaction.
dihydropyrimidinase deficiency
A high-throughput denaturing high-performance liquid chromatography method for the identification of variant alleles associated with dihydropyrimidine dehydrogenase deficiency.
dihydropyrimidinase deficiency
A Japanese Patient with Gastric Cancer and Dihydropyrimidine Dehydrogenase Deficiency Presenting with DPYD Variants.
dihydropyrimidinase deficiency
A mild phenotype of dihydropyrimidine dehydrogenase deficiency and developmental retardation associated with a missense mutation affecting cofactor binding.
dihydropyrimidinase deficiency
A novel stop-gain mutation in DPYS gene causing Dihidropyrimidinase deficiency, a case report.
dihydropyrimidinase deficiency
A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiency.
dihydropyrimidinase deficiency
A screening method for dihydropyrimidine dehydrogenase deficiency with colorimetric detection of urinary uracil.
dihydropyrimidinase deficiency
A simple and fast LC-MS/MS method with a very high sensitivity for the measurement of raltitrexed in human plasma.
dihydropyrimidinase deficiency
Altered Pre-mRNA Splicing Caused by a Novel Intronic Mutation c.1443+5G>A in the Dihydropyrimidinase (DPYS) Gene.
dihydropyrimidinase deficiency
An incidental case of dihydropyrimidine dehydrogenase deficiency: One case, multiple challenges.
dihydropyrimidinase deficiency
Analysis of severely affected patients with dihydropyrimidine dehydrogenase deficiency reveals large intragenic rearrangements of DPYD and a de novo interstitial deletion del(1)(p13.3p21.3).
dihydropyrimidinase deficiency
Application of metabolomic principles to disorders of nucleotide metabolism reveals new metabolic perturbations.
dihydropyrimidinase deficiency
Association of new deletion/duplication region at chromosome 1p21 with intellectual disability, severe speech deficit and autism spectrum disorder-like behavior: an all-in approach to solving the DPYD enigma.
dihydropyrimidinase deficiency
Autism: Screening of inborn errors of metabolism and unexpected results.
dihydropyrimidinase deficiency
Automated screening system for purine and pyrimidine metabolism disorders using high-performance liquid chromatography.
dihydropyrimidinase deficiency
Beta-alanine and beta-aminoisobutyric acid levels in two siblings with dihydropyrimidinase deficiency.
dihydropyrimidinase deficiency
Capecitabine Toxicity and Dihydropyrimidine Dehydrogenase Deficiency.
dihydropyrimidinase deficiency
Capecitabine-based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency.
dihydropyrimidinase deficiency
Clinical and biochemical abnormalities in a patient with dihydropyrimidine dehydrogenase deficiency due to homozygosity for the C29R mutation.
dihydropyrimidinase deficiency
Clinical and biochemical aspects of dihydropyrimidinase deficiency.
dihydropyrimidinase deficiency
Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance.
dihydropyrimidinase deficiency
Clinical variability in three Danish patients with dihydropyrimidine dehydrogenase deficiency all homozygous for the same mutation.
dihydropyrimidinase deficiency
Clinical, biochemical and genetic findings in two siblings with a dihydropyrimidinase deficiency.
dihydropyrimidinase deficiency
Comparative study of thymine and uracil metabolism in healthy persons and in a patient with dihydropyrimidine dehydrogenase deficiency.
dihydropyrimidinase deficiency
Cost Implications of Reactive Versus Prospective Testing for Dihydropyrimidine Dehydrogenase Deficiency in Patients With Colorectal Cancer: A Single-Institution Experience.
dihydropyrimidinase deficiency
Current insights into the impact of dihydropyrimidine dehydrogenase deficiency in patients receiving treatment with 5-fluorouracil.
dihydropyrimidinase deficiency
Cytomegalovirus enterocolitis in a patient with dihydropyrimidine dehydrogenase deficiency after capecitabine treatment: A case report.
dihydropyrimidinase deficiency
Delaying Centrifugation and Freezing by Adding a Dihydropyrimidine Dehydrogenase Inhibitor Such as Gimeracil to Blood Sample Is Not a Valid Option to Simplify the Preanalytic Step for the Screening of Dihydropyrimidine Dehydrogenase Deficiency Using Uracilemia.
dihydropyrimidinase deficiency
Detection of complete Dihydropyrimidine Dehydrogenase deficiency in a Tunisian family using a simple phenotypic test.
dihydropyrimidinase deficiency
Development and characterization of a monoclonal antibody with cross-reactivity towards uracil and thymine, and its potential use in screening patients treated with 5-fluorouracil for possible risks.
dihydropyrimidinase deficiency
Diagnosis of dihydropyrimidinase deficiency in a Chinese boy with dihydropyrimidinuria.
dihydropyrimidinase deficiency
Diagnosis of dihydropyrimidine dehydrogenase deficiency in a neonate with thymine-uraciluria.
dihydropyrimidinase deficiency
Diagnostic analysis, clinical importance and molecular basis of dihydropyrimidine dehydrogenase deficiency.
dihydropyrimidinase deficiency
Dihydropyrimidinase deficiency and congenital microvillous atrophy: coincidence or genetic relation?
dihydropyrimidinase deficiency
Dihydropyrimidinase deficiency and severe 5-fluorouracil toxicity.
dihydropyrimidinase deficiency
Dihydropyrimidinase deficiency in four East Asian patients due to novel and rare DPYS mutations affecting protein structural integrity and catalytic activity.
dihydropyrimidinase deficiency
Dihydropyrimidinase deficiency presenting in infancy with severe developmental delay.
dihydropyrimidinase deficiency
Dihydropyrimidinase deficiency, a progressive neurological disorder?
dihydropyrimidinase deficiency
Dihydropyrimidinase deficiency: confirmation of the enzyme defect in dihydropyrimidinuria.
dihydropyrimidinase deficiency
Dihydropyrimidinase deficiency: Phenotype, genotype and structural consequences in 17 patients.
dihydropyrimidinase deficiency
Dihydropyrimidinase deficiency: structural organization, chromosomal localization, and mutation analysis of the human dihydropyrimidinase gene.
dihydropyrimidinase deficiency
Dihydropyrimidinase deficiency: the first feline case of dihydropyrimidinuria with clinical and molecular findings.
dihydropyrimidinase deficiency
DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY (DPD) IN GI MALIGNANCIES: EXPERIENCE OF 4-YEARS.
dihydropyrimidinase deficiency
Dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil associated toxicity.
dihydropyrimidinase deficiency
Dihydropyrimidine dehydrogenase deficiency and acute neurological presentation.
dihydropyrimidinase deficiency
Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity.
dihydropyrimidinase deficiency
Dihydropyrimidine dehydrogenase deficiency as a cause of fatal 5-Fluorouracil toxicity.
dihydropyrimidinase deficiency
Dihydropyrimidine dehydrogenase deficiency caused by a novel genomic deletion c.505_513del of DPYD.
dihydropyrimidinase deficiency
Dihydropyrimidine dehydrogenase deficiency in a Hutterite newborn.
dihydropyrimidinase deficiency
Dihydropyrimidine dehydrogenase deficiency in an Indian population.
dihydropyrimidinase deficiency
Dihydropyrimidine dehydrogenase deficiency in patients with severe toxicity after 5-fluorouracil: a retrospective single-center study.
dihydropyrimidinase deficiency
Dihydropyrimidine dehydrogenase deficiency in two malaysian siblings with abnormal MRI findings.
dihydropyrimidinase deficiency
Dihydropyrimidine dehydrogenase deficiency leading to thymine-uraciluria. An inborn error of pyrimidine metabolism.
dihydropyrimidinase deficiency
Dihydropyrimidine dehydrogenase deficiency presenting at birth.
dihydropyrimidinase deficiency
Dihydropyrimidine dehydrogenase deficiency presenting with psychomotor retardation and ocular abnormalities.
dihydropyrimidinase deficiency
Dihydropyrimidine dehydrogenase deficiency presenting with psychomotor retardation in the first Polish patient.
dihydropyrimidinase deficiency
Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration.
dihydropyrimidinase deficiency
Dihydropyrimidine dehydrogenase deficiency. Identification of two novel mutations and expression of missense mutations in E. coli.
dihydropyrimidinase deficiency
Dihydropyrimidine dehydrogenase deficiency. Neurological aspects.
dihydropyrimidinase deficiency
Dihydropyrimidine dehydrogenase deficiency: a novel mutation and expression of missense mutations in E. coli.
dihydropyrimidinase deficiency
Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy.
dihydropyrimidinase deficiency
Dihydropyrimidine dehydrogenase deficiency: a potential etiology for 5-fluorouracil-induced neurotoxicity.
dihydropyrimidinase deficiency
Dihydropyrimidine Dehydrogenase Deficiency: Homozygosity for an Extremely Rare Variant in DPYD due to Uniparental Isodisomy of Chromosome 1.
dihydropyrimidinase deficiency
Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-Fluorouracil therapy.
dihydropyrimidinase deficiency
Dihydropyrimidine Dehydrogenase Deficiency: Metabolic Disease or Biochemical Phenotype?
dihydropyrimidinase deficiency
Dihydropyrimidine Dehydrogenase Deficiency: To Screen or Not to Screen?
dihydropyrimidinase deficiency
DPYD Exome, mRNA Expression and Uracil Levels in Early Severe Toxicity to Fluoropyrimidines: An Extreme Phenotype Approach.
dihydropyrimidinase deficiency
Dual Diagnosis of Dihydropyrimidine Dehydrogenase Deficiency and GM(1) Gangliosidosis.
dihydropyrimidinase deficiency
Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis.
dihydropyrimidinase deficiency
Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity.
dihydropyrimidinase deficiency
Encephalopathy secondary to capecitabine chemotherapy: a case report and discussion.
dihydropyrimidinase deficiency
Erratum: Publisher Correction to: Severe adverse events due to dihydropyrimidine dehydrogenase deficiency in a Japanese patient with colon cancer taking capecitabine: a case report.
dihydropyrimidinase deficiency
Evaluation of 5-fluorouracil pharmacokinetic models and therapeutic drug monitoring in cancer patients.
dihydropyrimidinase deficiency
Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency.
dihydropyrimidinase deficiency
Exposure-response analysis of Raltitrexed assessing liver toxicity.
dihydropyrimidinase deficiency
Fluoropyrimidine-induced toxicity and DPD deficiency.. A case report of early onset, lethal capecitabine-induced toxicity and mini review of the literature. Uridine triacetate: Efficacy and safety as an antidote. Is it accessible outside USA?
dihydropyrimidinase deficiency
From sequence and structure of sulfotransferases and dihydropyrimidinases to an understanding of their mechanisms of action and function.
dihydropyrimidinase deficiency
Genetic polymorphisms of dihydropyrimidinase in a Japanese patient with capecitabine-induced toxicity.
dihydropyrimidinase deficiency
Genetic regulation of beta-ureidopropionase and its possible implication in altered uracil catabolism.
dihydropyrimidinase deficiency
Genome sequencing reveals a novel genetic mechanism underlying dihydropyrimidine dehydrogenase deficiency: A novel missense variant c.1700G>A and a large intragenic inversion in DPYD spanning intron 8 to intron 12.
dihydropyrimidinase deficiency
Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency.
dihydropyrimidinase deficiency
Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratio.
dihydropyrimidinase deficiency
Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine.
dihydropyrimidinase deficiency
Head imaging abnormalities in dihydropyrimidine dehydrogenase deficiency.
dihydropyrimidinase deficiency
High-resolution melting analysis of the common c.1905+1G>A mutation causing dihydropyrimidine dehydrogenase deficiency and lethal 5-fluorouracil toxicity.
dihydropyrimidinase deficiency
Hyperammonemic encephalopathy during XELOX regimen. Is it capecitabine or oxaliplatin responsible?
dihydropyrimidinase deficiency
Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians.
dihydropyrimidinase deficiency
Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation.
dihydropyrimidinase deficiency
Lethal toxicity after 5-fluorouracil chemotherapy and its possible relationship to dihydropyrimidine dehydrogenase deficiency: a case report and review of the literature.
dihydropyrimidinase deficiency
Leukaemic expression of anaplastic large cell lymphoma with 46,XX,ins(2;5)(p23;q15q35) in a child with dihydropyrimidine dehydrogenase deficiency.
dihydropyrimidinase deficiency
Leukoencephalopathy with transient splenial lesions related to 5-fluorouracil or capecitabine.
dihydropyrimidinase deficiency
Metabolic approaches to the treatment of autism spectrum disorders.
dihydropyrimidinase deficiency
Methylation of the DPYD promoter and dihydropyrimidine dehydrogenase deficiency.
dihydropyrimidinase deficiency
Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients.
dihydropyrimidinase deficiency
Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity.
dihydropyrimidinase deficiency
New insights in dihydropyrimidine dehydrogenase deficiency: a pivotal role for beta-aminoisobutyric acid?
dihydropyrimidinase deficiency
Partial epilepsy in a girl with a symptom-free sister: first two Finnish patients with dihydropyrimidine dehydrogenase deficiency.
dihydropyrimidinase deficiency
Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency.
dihydropyrimidinase deficiency
Pitfalls in the diagnosis of patients with a partial dihydropyrimidine dehydrogenase deficiency.
dihydropyrimidinase deficiency
Possible prediction of adverse reactions to pyrimidine chemotherapy from urinary pyrimidine levels and a case of asymptomatic adult dihydropyrimidinuria.
dihydropyrimidinase deficiency
Pre- and post-dialysis quantitative dosage of thymidine in urine and plasma of a MNGIE patient by using HPLC-ESI-MS/MS.
dihydropyrimidinase deficiency
Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: A systemic review of current development, evidence, and recommendation.
dihydropyrimidinase deficiency
Preliminary Evidence for Enhanced Thymine Absorption: A Putative New Phenotype Associated With Fluoropyrimidine Toxicity in Cancer Patients.
dihydropyrimidinase deficiency
Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach.
dihydropyrimidinase deficiency
Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: The multiparametric approach is not convincing.
dihydropyrimidinase deficiency
Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy.
dihydropyrimidinase deficiency
Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype.
dihydropyrimidinase deficiency
Prolonged severe 5-fluorouracil-associated neurotoxicity in a patient with dihydropyrimidine dehydrogenase deficiency.
dihydropyrimidinase deficiency
Prompt treatment with uridine triacetate improves survival and reduces toxicity due to fluorouracil and capecitabine overdose or dihydropyrimidine dehydrogenase deficiency.
dihydropyrimidinase deficiency
Pyrimidine degradation defects and severe 5-fluorouracil toxicity.
dihydropyrimidinase deficiency
Radiochemical assay for determination of dihydropyrimidinase activity using reversed-phase high-performance liquid chromatography.
dihydropyrimidinase deficiency
Rapid gas chromatographic-mass spectrometric diagnosis of dihydropyrimidine dehydrogenase deficiency and dihydropyrimidinase deficiency.
dihydropyrimidinase deficiency
Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test.
dihydropyrimidinase deficiency
Rapid screening of high-risk patients for disorders of purine and pyrimidine metabolism using HPLC-electrospray tandem mass spectrometry of liquid urine or urine-soaked filter paper strips.
dihydropyrimidinase deficiency
Recommendation on testing for dihydropyrimidine dehydrogenase deficiency in the ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.
dihydropyrimidinase deficiency
Response to Letter: Cost Implications of Reactive Versus Prospective Testing for Dihydropyrimidine Dehydrogenase Deficiency in Patients With Colorectal Cancer: A Single-Institution Experience.
dihydropyrimidinase deficiency
Safe administration of irinotecan, oxaliplatin and raltitrexed in a DPD-deficient patient with metastatic colon cancer.
dihydropyrimidinase deficiency
Screening and diagnosis of beta-ureidopropionase deficiency by gas chromatographic/mass spectrometric analysis of urine.
dihydropyrimidinase deficiency
Screening for Dihydropyrimidine Dehydrogenase Deficiency: To Do or Not To Do, That's The Question.
dihydropyrimidinase deficiency
Screening for pyrimidine metabolism disorders using dried filter-paper urine samples: method development and a pilot study in Nagoya City, Japan.
dihydropyrimidinase deficiency
Severe 5-fluorouracil toxicity possibly secondary to dihydropyrimidine dehydrogenase deficiency in a breast cancer patient with osteogenesis imperfecta.
dihydropyrimidinase deficiency
Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome.
dihydropyrimidinase deficiency
Severe adverse events due to dihydropyrimidine dehydrogenase deficiency in a Japanese patient with colon cancer taking capecitabine: a case report.
dihydropyrimidinase deficiency
Severe fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency.
dihydropyrimidinase deficiency
Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency.
dihydropyrimidinase deficiency
Simple gas chromatographic-mass spectrometric procedure for diagnosing pyrimidine degradation defects for prevention of severe anticancer side effects.
dihydropyrimidinase deficiency
Successful use of uridine triacetate (Vistogard) three weeks after capecitabine in a patient with homozygous dihydropyrimidine dehydrogenase mutation: A case report and review of the literature.
dihydropyrimidinase deficiency
Tegafur-uracil (UFT) in lower doses is safe for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle.
dihydropyrimidinase deficiency
Tegafur-uracil is a safe alternative for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle.
dihydropyrimidinase deficiency
The dihydrouracil/uracil ratio in plasma, clinical and genetic analysis for screening of dihydropyrimidine dehydrogenase deficiency in colorectal cancer patients treated with 5-fluorouracil.
dihydropyrimidinase deficiency
The effect of dihydropyrimidine dehydrogenase deficiency on outcomes with fluorouracil.
dihydropyrimidinase deficiency
The first prenatal diagnosis of dihydropyrimidine dehydrogenase deficiency.
dihydropyrimidinase deficiency
Thirteen years experience with selective screening for disorders in purine and pyrimidine metabolism.
dihydropyrimidinase deficiency
Three different polymorphisms of the DPYD gene associated with severe toxicity following administration of 5-FU: a case report.
dihydropyrimidinase deficiency
Tolerability, Safety, and Outcomes of Neoadjuvant Chemoradiotherapy With Capecitabine for Patients Aged ? 70 Years With Locally Advanced Rectal Cancer.
dihydropyrimidinase deficiency
Topical application of 5-fluorouracil 5 percent cream associated with severe neutropenia: discussion of a case and review of systemic reactions after topical treatment with 5-fluorouracil.
dihydropyrimidinase deficiency
Toxicity Associated with Capecitabine in Patients Suffering from Dihydropyrimidine Dehydrogenase Deficiency.
dihydropyrimidinase deficiency
Unpredicted severe toxicity after 5-fluorouracil treatment due to dihydropyrimidine dehydrogenase deficiency.
dihydropyrimidinase deficiency
[A case in which dihydropyrimidine dehydrogenase deficiency was strongly suspected during adjuvant chemotherapy with capecitabine for colon cancer].
dihydropyrimidinase deficiency
[Analysis of gene variant in a Chinese child affected with dihydropyrimidinase deficiency].
dihydropyrimidinase deficiency
[Detection of dihydropyrimidine dehydrogenase deficiency before treatment by fluoropyrimidines]
dihydropyrimidinase deficiency
[Dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity]
dihydropyrimidinase deficiency
[Dihydropyrimidine dehydrogenase deficiency and toxicity to fluoropyrimidine]
dihydropyrimidinase deficiency
[Prerequisites to the administration and prevention of adverse effects of chemotherapy in colorectal cancer]
dihydropyrimidinase deficiency
[Severe 5-fluorouracil induced toxicity associated with dihydropyrimidine dehydrogenase deficiency]
dihydropyrimidinase deficiency
[Severe bone marrow suppression during adjuvant chemotherapy for gastric cancer by S-1 and its possible relationship to dihydropyrimidine dehydrogenase deficiency]
dihydropyrimidinase deficiency
[Severe toxicity after treatment with capecitabine and fluorouracil due to partial dihydropyrimidine dehydrogenase deficiency]
dihydropyrimidinase deficiency
[Suspected dihydropyrimidine dehydrogenase deficiency in a patient receiving capecitabine as adjuvant chemotherapy after colon resection].
Dihydropyrimidine Dehydrogenase Deficiency
5-Fluorouracil rechallenge after 5-fluorouracil-induced hyperammonemic encephalopathy.
Dihydropyrimidine Dehydrogenase Deficiency
5-Fluorouracil Rechallenge After Cardiotoxicity.
Dihydropyrimidine Dehydrogenase Deficiency
5-Fluorouracil-induced hyperammonaemic encephalopathy: A French national survey.
Dihydropyrimidine Dehydrogenase Deficiency
5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency.
Dihydropyrimidine Dehydrogenase Deficiency
5-FU multifocal inflammatory leukoencephalopathy and dihydropyrimidine dehydrogenase deficiency.
Dihydropyrimidine Dehydrogenase Deficiency
A bilateral cicatricial ectropion and bilateral upper lid shortening caused by 5-fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency.
Dihydropyrimidine Dehydrogenase Deficiency
A case of necrotic enteritis during neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic ductal adenocarcinoma.
Dihydropyrimidine Dehydrogenase Deficiency
A comprehensive population-based study comparing the phenotype and genotype in a pretherapeutic screen of dihydropyrimidine dehydrogenase deficiency.
Dihydropyrimidine Dehydrogenase Deficiency
A Facile Method for the Quantification of Urinary Uracil Concentration by a Uracil-Specific Fluorescence Derivatization Reaction.
Dihydropyrimidine Dehydrogenase Deficiency
A high-throughput denaturing high-performance liquid chromatography method for the identification of variant alleles associated with dihydropyrimidine dehydrogenase deficiency.
Dihydropyrimidine Dehydrogenase Deficiency
A Japanese Patient with Gastric Cancer and Dihydropyrimidine Dehydrogenase Deficiency Presenting with DPYD Variants.
Dihydropyrimidine Dehydrogenase Deficiency
A mild phenotype of dihydropyrimidine dehydrogenase deficiency and developmental retardation associated with a missense mutation affecting cofactor binding.
Dihydropyrimidine Dehydrogenase Deficiency
A new case of dihydropyrimidine dehydrogenase deficiency.
Dihydropyrimidine Dehydrogenase Deficiency
A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiency.
Dihydropyrimidine Dehydrogenase Deficiency
A screening method for dihydropyrimidine dehydrogenase deficiency with colorimetric detection of urinary uracil.
Dihydropyrimidine Dehydrogenase Deficiency
A simple and fast LC-MS/MS method with a very high sensitivity for the measurement of raltitrexed in human plasma.
Dihydropyrimidine Dehydrogenase Deficiency
An incidental case of dihydropyrimidine dehydrogenase deficiency: One case, multiple challenges.
Dihydropyrimidine Dehydrogenase Deficiency
Analysis of severely affected patients with dihydropyrimidine dehydrogenase deficiency reveals large intragenic rearrangements of DPYD and a de novo interstitial deletion del(1)(p13.3p21.3).
Dihydropyrimidine Dehydrogenase Deficiency
Application of metabolomic principles to disorders of nucleotide metabolism reveals new metabolic perturbations.
Dihydropyrimidine Dehydrogenase Deficiency
Association of new deletion/duplication region at chromosome 1p21 with intellectual disability, severe speech deficit and autism spectrum disorder-like behavior: an all-in approach to solving the DPYD enigma.
Dihydropyrimidine Dehydrogenase Deficiency
Autism: Screening of inborn errors of metabolism and unexpected results.
Dihydropyrimidine Dehydrogenase Deficiency
Automated screening system for purine and pyrimidine metabolism disorders using high-performance liquid chromatography.
Dihydropyrimidine Dehydrogenase Deficiency
Capecitabine Toxicity and Dihydropyrimidine Dehydrogenase Deficiency.
Dihydropyrimidine Dehydrogenase Deficiency
Capecitabine-based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency.
Dihydropyrimidine Dehydrogenase Deficiency
Clinical and biochemical abnormalities in a patient with dihydropyrimidine dehydrogenase deficiency due to homozygosity for the C29R mutation.
Dihydropyrimidine Dehydrogenase Deficiency
Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance.
Dihydropyrimidine Dehydrogenase Deficiency
Clinical variability in three Danish patients with dihydropyrimidine dehydrogenase deficiency all homozygous for the same mutation.
Dihydropyrimidine Dehydrogenase Deficiency
Comparative study of thymine and uracil metabolism in healthy persons and in a patient with dihydropyrimidine dehydrogenase deficiency.
Dihydropyrimidine Dehydrogenase Deficiency
Cost Implications of Reactive Versus Prospective Testing for Dihydropyrimidine Dehydrogenase Deficiency in Patients With Colorectal Cancer: A Single-Institution Experience.
Dihydropyrimidine Dehydrogenase Deficiency
Current insights into the impact of dihydropyrimidine dehydrogenase deficiency in patients receiving treatment with 5-fluorouracil.
Dihydropyrimidine Dehydrogenase Deficiency
Cytomegalovirus enterocolitis in a patient with dihydropyrimidine dehydrogenase deficiency after capecitabine treatment: A case report.
Dihydropyrimidine Dehydrogenase Deficiency
Delaying Centrifugation and Freezing by Adding a Dihydropyrimidine Dehydrogenase Inhibitor Such as Gimeracil to Blood Sample Is Not a Valid Option to Simplify the Preanalytic Step for the Screening of Dihydropyrimidine Dehydrogenase Deficiency Using Uracilemia.
Dihydropyrimidine Dehydrogenase Deficiency
Detection of complete Dihydropyrimidine Dehydrogenase deficiency in a Tunisian family using a simple phenotypic test.
Dihydropyrimidine Dehydrogenase Deficiency
Development and characterization of a monoclonal antibody with cross-reactivity towards uracil and thymine, and its potential use in screening patients treated with 5-fluorouracil for possible risks.
Dihydropyrimidine Dehydrogenase Deficiency
Development and validation of a rapid and sensitive UPLC-MS/MS method for determination of uracil and dihydrouracil in human plasma.
Dihydropyrimidine Dehydrogenase Deficiency
Diagnosis of dihydropyrimidinase deficiency in a Chinese boy with dihydropyrimidinuria.
Dihydropyrimidine Dehydrogenase Deficiency
Diagnosis of dihydropyrimidine dehydrogenase deficiency in a neonate with thymine-uraciluria.
Dihydropyrimidine Dehydrogenase Deficiency
Diagnostic analysis, clinical importance and molecular basis of dihydropyrimidine dehydrogenase deficiency.
Dihydropyrimidine Dehydrogenase Deficiency
Dihydropyrimidinase deficiency: confirmation of the enzyme defect in dihydropyrimidinuria.
Dihydropyrimidine Dehydrogenase Deficiency
Dihydropyrimidinase deficiency: structural organization, chromosomal localization, and mutation analysis of the human dihydropyrimidinase gene.
Dihydropyrimidine Dehydrogenase Deficiency
Dihydropyrimidinase deficiency: the first feline case of dihydropyrimidinuria with clinical and molecular findings.
Dihydropyrimidine Dehydrogenase Deficiency
DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY (DPD) IN GI MALIGNANCIES: EXPERIENCE OF 4-YEARS.
Dihydropyrimidine Dehydrogenase Deficiency
Dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil associated toxicity.
Dihydropyrimidine Dehydrogenase Deficiency
Dihydropyrimidine dehydrogenase deficiency and acute neurological presentation.
Dihydropyrimidine Dehydrogenase Deficiency
Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity.
Dihydropyrimidine Dehydrogenase Deficiency
Dihydropyrimidine dehydrogenase deficiency as a cause of fatal 5-Fluorouracil toxicity.
Dihydropyrimidine Dehydrogenase Deficiency
Dihydropyrimidine dehydrogenase deficiency caused by a novel genomic deletion c.505_513del of DPYD.
Dihydropyrimidine Dehydrogenase Deficiency
Dihydropyrimidine dehydrogenase deficiency in a Hutterite newborn.
Dihydropyrimidine Dehydrogenase Deficiency
Dihydropyrimidine dehydrogenase deficiency in an Indian population.
Dihydropyrimidine Dehydrogenase Deficiency
Dihydropyrimidine dehydrogenase deficiency in patients with severe toxicity after 5-fluorouracil: a retrospective single-center study.
Dihydropyrimidine Dehydrogenase Deficiency
Dihydropyrimidine dehydrogenase deficiency in two malaysian siblings with abnormal MRI findings.
Dihydropyrimidine Dehydrogenase Deficiency
Dihydropyrimidine dehydrogenase deficiency leading to thymine-uraciluria. An inborn error of pyrimidine metabolism.
Dihydropyrimidine Dehydrogenase Deficiency
Dihydropyrimidine dehydrogenase deficiency presenting at birth.
Dihydropyrimidine Dehydrogenase Deficiency
Dihydropyrimidine dehydrogenase deficiency presenting with psychomotor retardation and ocular abnormalities.
Dihydropyrimidine Dehydrogenase Deficiency
Dihydropyrimidine dehydrogenase deficiency presenting with psychomotor retardation in the first Polish patient.
Dihydropyrimidine Dehydrogenase Deficiency
Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration.
Dihydropyrimidine Dehydrogenase Deficiency
Dihydropyrimidine dehydrogenase deficiency. Identification of two novel mutations and expression of missense mutations in E. coli.
Dihydropyrimidine Dehydrogenase Deficiency
Dihydropyrimidine dehydrogenase deficiency. Neurological aspects.
Dihydropyrimidine Dehydrogenase Deficiency
Dihydropyrimidine dehydrogenase deficiency: a novel mutation and expression of missense mutations in E. coli.
Dihydropyrimidine Dehydrogenase Deficiency
Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy.
Dihydropyrimidine Dehydrogenase Deficiency
Dihydropyrimidine dehydrogenase deficiency: a potential etiology for 5-fluorouracil-induced neurotoxicity.
Dihydropyrimidine Dehydrogenase Deficiency
Dihydropyrimidine Dehydrogenase Deficiency: Homozygosity for an Extremely Rare Variant in DPYD due to Uniparental Isodisomy of Chromosome 1.
Dihydropyrimidine Dehydrogenase Deficiency
Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-Fluorouracil therapy.
Dihydropyrimidine Dehydrogenase Deficiency
Dihydropyrimidine Dehydrogenase Deficiency: Metabolic Disease or Biochemical Phenotype?
Dihydropyrimidine Dehydrogenase Deficiency
Dihydropyrimidine Dehydrogenase Deficiency: To Screen or Not to Screen?
Dihydropyrimidine Dehydrogenase Deficiency
DPYD Exome, mRNA Expression and Uracil Levels in Early Severe Toxicity to Fluoropyrimidines: An Extreme Phenotype Approach.
Dihydropyrimidine Dehydrogenase Deficiency
Dual Diagnosis of Dihydropyrimidine Dehydrogenase Deficiency and GM(1) Gangliosidosis.
Dihydropyrimidine Dehydrogenase Deficiency
Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis.
Dihydropyrimidine Dehydrogenase Deficiency
Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity.
Dihydropyrimidine Dehydrogenase Deficiency
Encephalopathy secondary to capecitabine chemotherapy: a case report and discussion.
Dihydropyrimidine Dehydrogenase Deficiency
Erratum: Publisher Correction to: Severe adverse events due to dihydropyrimidine dehydrogenase deficiency in a Japanese patient with colon cancer taking capecitabine: a case report.
Dihydropyrimidine Dehydrogenase Deficiency
Evaluation of 5-fluorouracil pharmacokinetic models and therapeutic drug monitoring in cancer patients.
Dihydropyrimidine Dehydrogenase Deficiency
Evaluation of 5-Fluorouracil Pharmacokinetics in Cancer Patients with a c.1905+1G>A Mutation in DPYD by Means of a Bayesian Limited Sampling Strategy.
Dihydropyrimidine Dehydrogenase Deficiency
Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency.
Dihydropyrimidine Dehydrogenase Deficiency
Exposure-response analysis of Raltitrexed assessing liver toxicity.
Dihydropyrimidine Dehydrogenase Deficiency
Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity.
Dihydropyrimidine Dehydrogenase Deficiency
Fluoropyrimidine-induced toxicity and DPD deficiency.. A case report of early onset, lethal capecitabine-induced toxicity and mini review of the literature. Uridine triacetate: Efficacy and safety as an antidote. Is it accessible outside USA?
Dihydropyrimidine Dehydrogenase Deficiency
Genetic regulation of dihydropyrimidinase and its possible implication in altered uracil catabolism.
Dihydropyrimidine Dehydrogenase Deficiency
Genome sequencing reveals a novel genetic mechanism underlying dihydropyrimidine dehydrogenase deficiency: A novel missense variant c.1700G>A and a large intragenic inversion in DPYD spanning intron 8 to intron 12.
Dihydropyrimidine Dehydrogenase Deficiency
Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency.
Dihydropyrimidine Dehydrogenase Deficiency
Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratio.
Dihydropyrimidine Dehydrogenase Deficiency
Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine.
Dihydropyrimidine Dehydrogenase Deficiency
Head imaging abnormalities in dihydropyrimidine dehydrogenase deficiency.
Dihydropyrimidine Dehydrogenase Deficiency
High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity.
Dihydropyrimidine Dehydrogenase Deficiency
High-resolution melting analysis of the common c.1905+1G>A mutation causing dihydropyrimidine dehydrogenase deficiency and lethal 5-fluorouracil toxicity.
Dihydropyrimidine Dehydrogenase Deficiency
Hyperammonemic encephalopathy during XELOX regimen. Is it capecitabine or oxaliplatin responsible?
Dihydropyrimidine Dehydrogenase Deficiency
Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians.
Dihydropyrimidine Dehydrogenase Deficiency
Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation.
Dihydropyrimidine Dehydrogenase Deficiency
Individualized Dosing of Fluoropyrimidine-Based Chemotherapy to Prevent Severe Fluoropyrimidine-Related Toxicity: What Are the Options?
Dihydropyrimidine Dehydrogenase Deficiency
Individualizing chemotherapeutic treatment of colorectal cancer.
Dihydropyrimidine Dehydrogenase Deficiency
Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency.
Dihydropyrimidine Dehydrogenase Deficiency
Lethal toxicity after 5-fluorouracil chemotherapy and its possible relationship to dihydropyrimidine dehydrogenase deficiency: a case report and review of the literature.
Dihydropyrimidine Dehydrogenase Deficiency
Leukaemic expression of anaplastic large cell lymphoma with 46,XX,ins(2;5)(p23;q15q35) in a child with dihydropyrimidine dehydrogenase deficiency.
Dihydropyrimidine Dehydrogenase Deficiency
Leukoencephalopathy with transient splenial lesions related to 5-fluorouracil or capecitabine.
Dihydropyrimidine Dehydrogenase Deficiency
Life-Threatening Reaction with Topical 5-Fluorouracil.
Dihydropyrimidine Dehydrogenase Deficiency
Metabolic approaches to the treatment of autism spectrum disorders.
Dihydropyrimidine Dehydrogenase Deficiency
Methylation of the DPYD promoter and dihydropyrimidine dehydrogenase deficiency.
Dihydropyrimidine Dehydrogenase Deficiency
Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients.
Dihydropyrimidine Dehydrogenase Deficiency
Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity.
Dihydropyrimidine Dehydrogenase Deficiency
Multiple organ failure due to 5-fluorouracil chemotherapy in a patient with a rare dihydropyrimidine dehydrogenase gene variant.
Dihydropyrimidine Dehydrogenase Deficiency
New insights in dihydropyrimidine dehydrogenase deficiency: a pivotal role for beta-aminoisobutyric acid?
Dihydropyrimidine Dehydrogenase Deficiency
Partial epilepsy in a girl with a symptom-free sister: first two Finnish patients with dihydropyrimidine dehydrogenase deficiency.
Dihydropyrimidine Dehydrogenase Deficiency
Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency.
Dihydropyrimidine Dehydrogenase Deficiency
Pitfalls in the diagnosis of patients with a partial dihydropyrimidine dehydrogenase deficiency.
Dihydropyrimidine Dehydrogenase Deficiency
Porous graphitic carbon shows promise for the rapid screening partial DPD deficiency in lymphocyte dihydropyrimidine dehydrogenase in Chinese, Indian and Malay in Singapore by using semi-automated HPLC-radioassay.
Dihydropyrimidine Dehydrogenase Deficiency
Possible prediction of adverse reactions to fluorouracil by the measurement of urinary dihydrothymine and thymine.
Dihydropyrimidine Dehydrogenase Deficiency
Possible prediction of adverse reactions to pyrimidine chemotherapy from urinary pyrimidine levels and a case of asymptomatic adult dihydropyrimidinuria.
Dihydropyrimidine Dehydrogenase Deficiency
Pre- and post-dialysis quantitative dosage of thymidine in urine and plasma of a MNGIE patient by using HPLC-ESI-MS/MS.
Dihydropyrimidine Dehydrogenase Deficiency
Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: A systemic review of current development, evidence, and recommendation.
Dihydropyrimidine Dehydrogenase Deficiency
Preemptive screening of DPYD as part of clinical practice: high prevalence of a novel exon 4 deletion in the Finnish population.
Dihydropyrimidine Dehydrogenase Deficiency
Preliminary Evidence for Enhanced Thymine Absorption: A Putative New Phenotype Associated With Fluoropyrimidine Toxicity in Cancer Patients.
Dihydropyrimidine Dehydrogenase Deficiency
Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach.
Dihydropyrimidine Dehydrogenase Deficiency
Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: The multiparametric approach is not convincing.
Dihydropyrimidine Dehydrogenase Deficiency
Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy.
Dihydropyrimidine Dehydrogenase Deficiency
Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype.
Dihydropyrimidine Dehydrogenase Deficiency
Prolonged severe 5-fluorouracil-associated neurotoxicity in a patient with dihydropyrimidine dehydrogenase deficiency.
Dihydropyrimidine Dehydrogenase Deficiency
Prompt treatment with uridine triacetate improves survival and reduces toxicity due to fluorouracil and capecitabine overdose or dihydropyrimidine dehydrogenase deficiency.
Dihydropyrimidine Dehydrogenase Deficiency
Pyrimidine degradation defects and severe 5-fluorouracil toxicity.
Dihydropyrimidine Dehydrogenase Deficiency
Rapid gas chromatographic-mass spectrometric diagnosis of dihydropyrimidine dehydrogenase deficiency and dihydropyrimidinase deficiency.
Dihydropyrimidine Dehydrogenase Deficiency
Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test.
Dihydropyrimidine Dehydrogenase Deficiency
Rapid screening of high-risk patients for disorders of purine and pyrimidine metabolism using HPLC-electrospray tandem mass spectrometry of liquid urine or urine-soaked filter paper strips.
Dihydropyrimidine Dehydrogenase Deficiency
Recommendation on testing for dihydropyrimidine dehydrogenase deficiency in the ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.
Dihydropyrimidine Dehydrogenase Deficiency
Response to Letter: Cost Implications of Reactive Versus Prospective Testing for Dihydropyrimidine Dehydrogenase Deficiency in Patients With Colorectal Cancer: A Single-Institution Experience.
Dihydropyrimidine Dehydrogenase Deficiency
Safe administration of irinotecan, oxaliplatin and raltitrexed in a DPD-deficient patient with metastatic colon cancer.
Dihydropyrimidine Dehydrogenase Deficiency
Screening for dihydropyrimidine dehydrogenase deficiency.
Dihydropyrimidine Dehydrogenase Deficiency
Screening for Dihydropyrimidine Dehydrogenase Deficiency: To Do or Not To Do, That's The Question.
Dihydropyrimidine Dehydrogenase Deficiency
Screening for pyrimidine metabolism disorders using dried filter-paper urine samples: method development and a pilot study in Nagoya City, Japan.
Dihydropyrimidine Dehydrogenase Deficiency
Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity.
Dihydropyrimidine Dehydrogenase Deficiency
Severe 5-fluorouracil toxicity possibly secondary to dihydropyrimidine dehydrogenase deficiency in a breast cancer patient with osteogenesis imperfecta.
Dihydropyrimidine Dehydrogenase Deficiency
Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome.
Dihydropyrimidine Dehydrogenase Deficiency
Severe adverse events due to dihydropyrimidine dehydrogenase deficiency in a Japanese patient with colon cancer taking capecitabine: a case report.
Dihydropyrimidine Dehydrogenase Deficiency
Severe fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency.
Dihydropyrimidine Dehydrogenase Deficiency
Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency.
Dihydropyrimidine Dehydrogenase Deficiency
Simple gas chromatographic-mass spectrometric procedure for diagnosing pyrimidine degradation defects for prevention of severe anticancer side effects.
Dihydropyrimidine Dehydrogenase Deficiency
Successful use of uridine triacetate (Vistogard) three weeks after capecitabine in a patient with homozygous dihydropyrimidine dehydrogenase mutation: A case report and review of the literature.
Dihydropyrimidine Dehydrogenase Deficiency
Tegafur-uracil (UFT) in lower doses is safe for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle.
Dihydropyrimidine Dehydrogenase Deficiency
Tegafur-uracil is a safe alternative for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle.
Dihydropyrimidine Dehydrogenase Deficiency
The contribution of deleterious DPYD gene sequence variants to fluoropyrimidine toxicity in British cancer patients.
Dihydropyrimidine Dehydrogenase Deficiency
The dihydrouracil/uracil ratio in plasma, clinical and genetic analysis for screening of dihydropyrimidine dehydrogenase deficiency in colorectal cancer patients treated with 5-fluorouracil.
Dihydropyrimidine Dehydrogenase Deficiency
The effect of dihydropyrimidine dehydrogenase deficiency on outcomes with fluorouracil.
Dihydropyrimidine Dehydrogenase Deficiency
The first prenatal diagnosis of dihydropyrimidine dehydrogenase deficiency.
Dihydropyrimidine Dehydrogenase Deficiency
Thirteen years experience with selective screening for disorders in purine and pyrimidine metabolism.
Dihydropyrimidine Dehydrogenase Deficiency
Three different polymorphisms of the DPYD gene associated with severe toxicity following administration of 5-FU: a case report.
Dihydropyrimidine Dehydrogenase Deficiency
Tolerability, Safety, and Outcomes of Neoadjuvant Chemoradiotherapy With Capecitabine for Patients Aged ? 70 Years With Locally Advanced Rectal Cancer.
Dihydropyrimidine Dehydrogenase Deficiency
Topical application of 5-fluorouracil 5 percent cream associated with severe neutropenia: discussion of a case and review of systemic reactions after topical treatment with 5-fluorouracil.
Dihydropyrimidine Dehydrogenase Deficiency
Toxicity Associated with Capecitabine in Patients Suffering from Dihydropyrimidine Dehydrogenase Deficiency.
Dihydropyrimidine Dehydrogenase Deficiency
Unpredicted severe toxicity after 5-fluorouracil treatment due to dihydropyrimidine dehydrogenase deficiency.
Dihydropyrimidine Dehydrogenase Deficiency
[A case in which dihydropyrimidine dehydrogenase deficiency was strongly suspected during adjuvant chemotherapy with capecitabine for colon cancer].
Dihydropyrimidine Dehydrogenase Deficiency
[Detection of dihydropyrimidine dehydrogenase deficiency before treatment by fluoropyrimidines]
Dihydropyrimidine Dehydrogenase Deficiency
[Dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity]
Dihydropyrimidine Dehydrogenase Deficiency
[Dihydropyrimidine dehydrogenase deficiency and toxicity to fluoropyrimidine]
Dihydropyrimidine Dehydrogenase Deficiency
[Dihydropyrimidine dehydrogenase deficiency]
Dihydropyrimidine Dehydrogenase Deficiency
[Prerequisites to the administration and prevention of adverse effects of chemotherapy in colorectal cancer]
Dihydropyrimidine Dehydrogenase Deficiency
[Severe 5-fluorouracil induced toxicity associated with dihydropyrimidine dehydrogenase deficiency]
Dihydropyrimidine Dehydrogenase Deficiency
[Severe bone marrow suppression during adjuvant chemotherapy for gastric cancer by S-1 and its possible relationship to dihydropyrimidine dehydrogenase deficiency]
Dihydropyrimidine Dehydrogenase Deficiency
[Severe toxicity after treatment with capecitabine and fluorouracil due to partial dihydropyrimidine dehydrogenase deficiency]
Dihydropyrimidine Dehydrogenase Deficiency
[Suspected dihydropyrimidine dehydrogenase deficiency in a patient receiving capecitabine as adjuvant chemotherapy after colon resection].
Distemper
Effects of subclinical inflammation on C-reactive protein and haptoglobin levels as well as specific humoral immunity in dogs vaccinated against canine distemper and parvovirus.
Down Syndrome
Aberrant expression of dihydropyrimidinase related proteins-2,-3 and -4 in fetal Down syndrome brain.
Down Syndrome
Expression of the dihydropyrimidinase related protein 2 (DRP-2) in Down syndrome and Alzheimer's disease brain is downregulated at the mRNA and dysregulated at the protein level.
Drug-Related Side Effects and Adverse Reactions
DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients.
Drug-Related Side Effects and Adverse Reactions
Predicting drug response and toxicity based on gene polymorphisms.
Drug-Related Side Effects and Adverse Reactions
Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean population for prediction of 5-fluorouracil-associated toxicity.
Drug-Related Side Effects and Adverse Reactions
Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients.
Ectropion
A bilateral cicatricial ectropion and bilateral upper lid shortening caused by 5-fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency.
Endotoxemia
Direct hemoperfusion with polymyxin B-immobilized fiber improves shock and hypoxemia during endotoxemia in anesthetized sheep.
Endotoxemia
Endotoxin removal by direct hemoperfusion with an adsorbent column using polymyxin B-immobilized fiber ameliorates systemic circulatory disturbance in patients with septic shock.
Enteritis
A case of necrotic enteritis during neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic ductal adenocarcinoma.
Enterocolitis
Cytomegalovirus enterocolitis in a patient with dihydropyrimidine dehydrogenase deficiency after capecitabine treatment: A case report.
Epilepsies, Partial
Partial epilepsy in a girl with a symptom-free sister: first two Finnish patients with dihydropyrimidine dehydrogenase deficiency.
Escherichia coli Infections
Enhancement of resistance to Escherichia coli infection in mice by dihydroheptaprenol, a synthetic polyprenol derivative.
Esophageal Neoplasms
Dihydropyrimidine dehydrogenase and orotate phosphoribosyltransferase in esophageal cancer patients: Correlation with clinicopathological factors and prognosis.
Esophageal Neoplasms
Role of dihydropyrimidine dehydrogenase activity in patients with esophageal cancer.
Esophageal Neoplasms
Roles of thymidylate synthase and dihydropyrimidine dehydrogenase expression in blood as predictors of response to multimodal therapy in esophageal cancer.
Esophageal Neoplasms
Thymidylate synthetase and dihydropyrimidine dehydrogenase mRNA levels in esophageal cancer.
Esophageal Neoplasms
[Correlation between clinicopathological factors and enzymatic activity of orotate phosphoribosyl transferase (OPRT), dihydropyrimidine dehydrogenase (DPD) in esophageal cancer]
Esophageal Neoplasms
[Immunohistochemical study of dihydropyrimidine dehydrogenase (DPD) and p53 in biopsied specimens of esophageal cancer before chemoradiotherapy]
Esophageal Squamous Cell Carcinoma
Novel 5-fluorouracil-resistant human esophageal squamous cell carcinoma cells with dihydropyrimidine dehydrogenase overexpression.
Esophageal Squamous Cell Carcinoma
Thymidylate synthetase and dihydropyrimidine dehydrogenase mRNA levels in esophageal cancer.
Esophageal Stenosis
A unique case of a patient with rectal cancer who developed benign esophageal stenosis after localized rectal radiation and systemic chemotherapy.
Fanconi Anemia
Biomarker analysis in patients with advanced gastric cancer treated with S-1 plus cisplatin chemotherapy: orotate phosphoribosyltransferase expression is associated with treatment outcomes.
Fetal Growth Retardation
Comparative developmental toxicity evaluation of di- n-hexyl phthalate and dicyclohexyl phthalate in rats.
Gait Disorders, Neurologic
Peripheral neuropathy associated with weekly oral 5-fluorouracil, leucovorin and eniluracil.
Gallbladder Neoplasms
Thymidylate synthase and dihydropyrimidine dehydrogenase expressions in gallbladder cancer.
Gangliosidoses
Dual Diagnosis of Dihydropyrimidine Dehydrogenase Deficiency and GM(1) Gangliosidosis.
Gastrointestinal Neoplasms
Correlation of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase with sensitivity of gastrointestinal cancer cells to 5-fluorouracil and 5-fluoro-2'-deoxyuridine.
Gastrointestinal Neoplasms
Dihydropyrimidine dehydrogenase, multidrug resistance-associated protein, and thymidylate synthase gene expression levels can predict 5-fluorouracil resistance in human gastrointestinal cancer cells.
Gastrointestinal Neoplasms
Discrepancies between the gene expression, protein expression, and enzymatic activity of thymidylate synthase and dihydropyrimidine dehydrogenase in human gastrointestinal cancers and adjacent normal mucosa.
Gastrointestinal Neoplasms
Efficacy of laser capture microdissection plus RT-PCR technique in analyzing gene expression levels in human gastric cancer and colon cancer.
Gastrointestinal Neoplasms
Expression levels of thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) in patients with gastrointestinal cancer.
Gastrointestinal Neoplasms
Impact of the expression of thymidylate synthase and dihydropyrimidine dehydrogenase genes on survival in stage II/III gastric cancer.
Gastrointestinal Neoplasms
Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5-FU-based chemotherapy.
Gastrointestinal Neoplasms
Is capecitabine safe in patients with gastrointestinal cancer and dihydropyrimidine dehydrogenase deficiency?
Gastrointestinal Neoplasms
Preoperative endoscopic analysis of thymidine phosphorylase and dihydropyrimidine dehydrogenase in gastrointestinal cancer.
Gastrointestinal Neoplasms
Promoter methylation and large intragenic rearrangements of DPYD are not implicated in severe toxicity to 5-fluorouracil-based chemotherapy in gastrointestinal cancer patients.
Gastrointestinal Neoplasms
Protein-bound polysaccharide-K augments the anticancer effect of fluoropyrimidine derivatives possibly by lowering dihydropyrimidine dehydrogenase expression in gastrointestinal cancers.
Gastrointestinal Neoplasms
Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in breast cancer predicts 5-FU sensitivity by a histocultural drug sensitivity test.
Genetic Diseases, Inborn
Double-stem Hairpin Probe and Ultrasensitive Colorimetric Detection of Cancer-related Nucleic Acids.
Gingival Overgrowth
Gingival overgrowth among renal transplant recipients and uraemic patients.
Glaucoma
[Basic and clinical studies of pressure-independent damaging factors of open angle glaucoma].
Glioma
Dihydropyrimidine Dehydrogenase Is a Prognostic Marker for Mesenchymal Stem Cell-Mediated Cytosine Deaminase Gene and 5-Fluorocytosine Prodrug Therapy for the Treatment of Recurrent Gliomas.
Glioma
Influence of 17beta-estradiol on the synthesis of reduced neurosteroids in the brain (in vivo) and in glioma cells (in vitro): possible relevance to mental disorders in women.
Glycogen Storage Disease
Autism: Screening of inborn errors of metabolism and unexpected results.
Gram-Negative Bacterial Infections
[Endotoxin eliminating therapy in patients with severe sepsis--direct hemoperfusion using polymyxin B immobilized fiber column]
Hand-Foot Syndrome
Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines?
Hand-Foot Syndrome
Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine.
Hand-Foot Syndrome
[A patient with recurrent gastric cancer who developed TS-1 induced hand-foot syndrome]
Head and Neck Neoplasms
A multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracil.
Head and Neck Neoplasms
Association of genetic variability in enzymes metabolizing chemotherapeutic agents with treatment response in head and neck cancer cases.
Head and Neck Neoplasms
Dihydropyrimidine dehydrogenase mutation in neoadjuvant chemotherapy in head and neck cancers: Myth or reality?
Head and Neck Neoplasms
Incidence and impact of Dihydropyrimidine dehydrogenase gene mutation on neoadjuvant chemotherapy in head and neck cancers.
Head and Neck Neoplasms
Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer.
Head and Neck Neoplasms
The predictive and therapeutic value of thymidine phosphorylase and dihydropyrimidine dehydrogenase in capecitabine (Xeloda)-based chemotherapy for head and neck cancer.
Head and Neck Neoplasms
ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabine.
Head and Neck Neoplasms
[Clinical efficacy of administration with S-1 alone for head and neck carcinoma]
Heart Arrest
Usefulness of venoarterial extracorporeal membranous oxygenation for fatal cibenzoline succinate poisoning.
Heart Diseases
Canine myocardial dihydropyridine binding sites: a positron emission tomographic study with the calcium channel inhibitor 11C-S11568.
Heart Failure
An animal model of dilated cardiomyopathy: characterization of dihydropyridine receptors and contractile performance.
Hematuria
Identification of two novel mutations C79X and R235Q in the dihydropyrimidine dehydrogenase gene in a patient presenting with hematuria.
Hepatitis A
Effects of subclinical inflammation on C-reactive protein and haptoglobin levels as well as specific humoral immunity in dogs vaccinated against canine distemper and parvovirus.
Hepatitis C
Genetic polymorphisms of enzymes related to oral tegafur/uracil therapeutic efficacy in patients with hepatocellular carcinoma.
Herpes Zoster
Identical inhibitory modulation of A-type potassium currents by dihydropyridine calcium channel agonists and antagonists.
Herpes Zoster
Inhibition of dihydropyrimidine dehydrogenase by 5-propynyluracil, a metabolite of the anti-varicella zoster virus agent netivudine.
Herpes Zoster
The effect of sorivudine on dihydropyrimidine dehydrogenase activity in patients with acute herpes zoster.
Hyperglycemia
Different antioxidative potencies of dihydropyridine calcium channel modulators in various models.
Hypersensitivity, Delayed
Delayed hypersensitivity to 5-fluorouracil associated with reduced dihydropyrimidine dehydrogenase (DPD) activity.
Hypertension
Antihypertensive agents and the risk of breast cancer in women aged 55 years and older: a nested case-control study.
Hypertension
Calcium channel blockers for hypertension: dissecting the evidence for adverse effects.
Hypertension
Central cardiovascular effects of dihydropyridines in spontaneously hypertensive rats.
Hypertension
Central interactions between dihydropyridines and cholinergic systems in the control of blood pressure in rat.
Hypertension
Risk of myocardial infarction with combination antihypertensive regimens including a dihydropyridine calcium channel blocker in hypertensive diabetics.
Hypertension
Synthesis and selective vasodilating properties of esters of 2,6-dimethyl-4-(2-difluoromethoxyphenyl)-1,4-dihydro-pyridine-3,5-di- carboxylic acid.
Hypertension, Renovascular
Effects of m-nifedipine on dihydropyridine binding sites in cardiac and cerebral cortex cell membranes from left ventricular hypertrophied rats.
Hypertension, Renovascular
Effects of menidipine on dihydropyridines binding sites in cardiac and cerebral membranes from old rats with left ventricular hypertrophy.
Hypertension, Renovascular
[Effects of m-nifedipine on dihydropyridine binding sites in the cell membranes of kidney and lung from left ventricular hypertrophied elderly rats]
Hypertrophy, Left Ventricular
Calcium channel blockers for hypertension: dissecting the evidence for adverse effects.
Hypesthesia
Peripheral neuropathy associated with weekly oral 5-fluorouracil, leucovorin and eniluracil.
Hypobetalipoproteinemias
Autism: Screening of inborn errors of metabolism and unexpected results.
Hypokalemic Periodic Paralysis
Altered calcium currents in human hypokalemic periodic paralysis myotubes expressing mutant L-type calcium channels.
Hypokalemic Periodic Paralysis
Dihydropyridine receptor mutations cause hypokalemic periodic paralysis.
Hypokalemic Periodic Paralysis
Genotype-phenotype correlations of DHP receptor alpha 1-subunit gene mutations causing hypokalemic periodic paralysis.
Hypokalemic Periodic Paralysis
Mutation in DHP receptor alpha 1 subunit (CACLN1A3) gene in a Dutch family with hypokalaemic periodic paralysis.
Hypotension
Direct hemoperfusion with polymyxin B-immobilized fiber improves shock and hypoxemia during endotoxemia in anesthetized sheep.
hypoxanthine phosphoribosyltransferase deficiency
Thirteen years experience with selective screening for disorders in purine and pyrimidine metabolism.
Infections
Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria.
Infections
Efficacy of artemether-lumefantrine versus dihydroartemisinin-piperaquine for the treatment of uncomplicated malaria among children in Rwanda: an open-label, randomized controlled trial.
Infections
Enhancement of resistance to Escherichia coli infection in mice by dihydroheptaprenol, a synthetic polyprenol derivative.
Infections
Folic acid induces salicylic acid-dependent immunity in Arabidopsis and enhances susceptibility to Alternaria brassicicola.
Infections
Prophylactic activity of dihydroheptaprenol, a synthetic polyprenol derivative, against Sendai virus infection in mice.
Infections
Protective effect of dihydroheptaprenol in combination with vaccine to experimental Actinobacillus pleuropneumoniae infection in guinea pigs and pigs.
Infections
Risk for dental healthcare professionals during the COVID-19 global pandemic: An evidence-based assessment.
Infections
[A new strategy for malignancies by direct hemoperfusion using bacterial endotoxin bounded fiber]
Intellectual Disability
An incidental case of dihydropyrimidine dehydrogenase deficiency: One case, multiple challenges.
Intellectual Disability
Dihydropyrimidine Dehydrogenase Deficiency: Homozygosity for an Extremely Rare Variant in DPYD due to Uniparental Isodisomy of Chromosome 1.
Intraabdominal Infections
[Meropenem (Merrem) vs imipenem/cilastatin in hospital treatment of intra-abdominal infections. A multicenter study]
Leukemia
Inhibitors of C1q biosynthesis suppress activation of murine macrophages for both antibody-independent and antibody-dependent tumor cytotoxicity.
Leukoencephalopathies
5-FU multifocal inflammatory leukoencephalopathy and dihydropyrimidine dehydrogenase deficiency.
Leukopenia
Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group.
Leukopenia
The impact of ABCC11 polymorphisms on the risk of early-onset fluoropyrimidine toxicity.
Liver Diseases
Influence of liver dysfunction on dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells.
Liver Failure, Acute
[For which cases should clinicians perform blood purification in the management of acute poisoning? Clinical and pharmacological analyses]
Liver Neoplasms
Thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in hepatocellular carcinoma and metastatic liver cancer.
Lordosis
Effects of genotype on differential behavioral responsiveness to progesterone and 5alpha-dihdroprogesterone in mice.
Lordosis
I. Levels of 5?-reduced progesterone metabolite in the midbrain account for variability in reproductive behavior of middle-aged female rats.
Lordosis
Ring A reduced progestins potently stimulate estrous behavior in rats: paradoxical effect through the progesterone receptor.
Low Tension Glaucoma
[Basic and clinical studies of pressure-independent damaging factors of open angle glaucoma].
Lung Injury
Direct hemoperfusion with polymyxin B-immobilized fiber improves shock and hypoxemia during endotoxemia in anesthetized sheep.
Lung Neoplasms
A feasibility study of postoperative adjuvant chemotherapy with fluoropyrimidine S-1 in patients with stage II-IIIA non-small cell lung cancer.
Lung Neoplasms
Comprehensive evaluation of the response of genes to the administration of the antitumor drug S-1 using a low density array.
Lung Neoplasms
Dihydropyrimidine dehydrogenase levels in nonsmall-cell lung cancer tissues.
Lung Neoplasms
Effects of UFT on thymidylate synthase and dihydropyrimidine dehydrogenase activities in lung cancer.
Lung Neoplasms
Epidermal growth factor signals regulate dihydropyrimidine dehydrogenase expression in EGFR-mutated non-small-cell lung cancer.
Lung Neoplasms
Feasibility study of postoperative adjuvant chemotherapy with S-1 (tegaful, gimeracil, oteracil potassium) for non-small cell lung cancer-LOGIK 0601 study.
Lung Neoplasms
High expression of dihydropyrimidine dehydrogenase in lung adenocarcinoma is associated with mutations in epidermal growth factor receptor: implications for the treatment of non--small-cell lung cancer using 5-fluorouracil.
Lung Neoplasms
In vitro sensitivity to platinum-derived drugs is associated with expression of thymidylate synthase and dihydropyrimidine dehydrogenase in human lung cancer.
Lung Neoplasms
Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5-FU-based chemotherapy.
Lung Neoplasms
Low thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase mRNA expression correlate with prolonged survival in resected non-small-cell lung cancer.
Lung Neoplasms
Predictive value of dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (Tegafur + Uracil) in patients with p-stage I nonsmall-cell lung cancer.
Lung Neoplasms
Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (tegafur+uracil) in patients with non-small cell lung cancer.
Lung Neoplasms
Synergistic antitumor activity of the SN-38-incorporating polymeric micelles NK012 with S-1 in a mouse model of Non-small cell lung cancer.
Lung Neoplasms
The relationship between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase, excision repair cross-complementation group 1 and class III ?-tubulin, and the therapeutic effect of S-1 or carboplatin plus paclitaxel in non-small-cell lung cancer.
Lung Neoplasms
The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fluorouracil in human lung cancer cells.
Lung Neoplasms
Thymidine phosphorylase levels and dihydropyrimidine dehydrogenase levels in non-small cell lung cancer tissues.
Lung Neoplasms
Thymidylate synthase and dihydropyrimidine dehydrogenase activities in non-small cell lung cancer tissues: relationship with in vitro sensitivity to 5-fluorouracil.
Lung Neoplasms
Thymidylate synthase and dihydropyrimidine dehydrogenase expression levels are associated with response to S-1 plus carboplatin in advanced non-small cell lung cancer.
Lung Neoplasms
Thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer: relationship between mRNA expression and activity.
Lung Neoplasms
Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA levels in tumor tissues and the efficacy of 5-fluorouracil in patients with non-small-cell lung cancer.
Lung Neoplasms
Thymidylate synthase expression is closely associated with outcome in patients with pulmonary adenocarcinoma.
Lung Neoplasms
Thymidylate Synthase, Dihydropyrimidine Dehydrogenase, Thymidine Phosphorylase, Orotate Phosphoribosyltransferase mRNA Expression in Lung Cancer Metastatic Lymph Node Samples Obtained by Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration - A Pilot Study.
Lymphatic Metastasis
Effects of UFT on thymidylate synthase and dihydropyrimidine dehydrogenase activities in lung cancer.
Lymphatic Metastasis
[Relationship between the anti-metastatic effect of UFT and in vitro chemosensitivity to 5-FU in metastatic tumors from orthotopic implanted colon cancer in nude rats]
Lymphoma
Leukaemic expression of anaplastic large cell lymphoma with 46,XX,ins(2;5)(p23;q15q35) in a child with dihydropyrimidine dehydrogenase deficiency.
Lymphoma, B-Cell
Predictive biomarkers for combined chemotherapy with 5-fluorouracil and cisplatin in oro- and hypopharyngeal cancers.
Lymphoma, Large-Cell, Anaplastic
Leukaemic expression of anaplastic large cell lymphoma with 46,XX,ins(2;5)(p23;q15q35) in a child with dihydropyrimidine dehydrogenase deficiency.
Malaria
A tablet derived from Andrographis paniculata complements dihydroartemisinin-piperaquine treatment of malaria in pregnant mice.
Malaria
Budget Impact Analysis of Using Dihydroartemisinin-Piperaquine to Treat Uncomplicated Malaria in Children in Tanzania.
Malaria
Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malaria.
Malaria
Efficacy of Artemisinin-Based Combination Treatments of Uncomplicated Falciparum Malaria in Under-Five-Year-Old Nigerian Children Ten Years Following Adoption as First-Line Antimalarials.
Malaria
Intravenous artesunate plus oral dihydroartemisinin-piperaquine or intravenous quinine plus oral quinine for optimum treatment of severe malaria: lesson learnt from a field hospital in Timika, Papua, Indonesia.
Malaria
Introducing post-discharge malaria chemoprevention (PMC) for management of severe anemia in Malawian children: a qualitative study of community health workers' perceptions and motivation.
Malaria
Open label randomized comparison of dihydroartemisinin-piperaquine and artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in central Vietnam.
Malaria
Randomized trials of artemisinin-piperaquine, dihydroartemisinin-piperaquine phosphate and artemether-lumefantrine for the treatment of multi-drug resistant falciparum malaria in Cambodia-Thailand border area.
Malaria
Single dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission in Cambodia: An open-label randomized trial.
Malaria
Treatment policy change to dihydroartemisinin-piperaquine contributes to the reduction of adverse maternal and pregnancy outcomes.
Malaria, Vivax
Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study.
Malnutrition
Dihydropyrimidinase deficiency: the first feline case of dihydropyrimidinuria with clinical and molecular findings.
Malnutrition
Is Health-Related Quality of Life an Independent Prognostic Factor For 12-Month Mortality and Nursing Home Placement among Elderly Patients Hospitalized via the Emergency Department?
Melanoma
Identification and characterization of dihydropyrimidinase inhibited by plumbagin isolated from Nepenthes miranda extract.
Melanoma
[111In]-DTPA-labeled analogues of alpha-melanocyte-stimulating hormone for melanoma targeting: receptor binding in vitro and in vivo.
Melanoma, Experimental
The effect of L-3, 4-dehydroproline on the antitumor activity and toxicity of bleomycin.
Metabolic Diseases
Dihydropyrimidine Dehydrogenase Deficiency: Metabolic Disease or Biochemical Phenotype?
Metabolic Syndrome
Dihydropyrimidinase deficiency: the first feline case of dihydropyrimidinuria with clinical and molecular findings.
Metabolic Syndrome
Unique atheroprotective property of azelnidipine, a dihydropyridine-based calcium antagonist.
Metabolism, Inborn Errors
A Critical Review on Clinical Application of Separation Techniques for Selective Recognition of Uracil and 5-Fluorouracil.
Mouth Neoplasms
[Immunohistochemical and clinicopathological study of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyl transferase expression in oral cancer patients responding to UFT]
Mucositis
Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group.
Mucositis
Tolerability, Safety, and Outcomes of Neoadjuvant Chemoradiotherapy With Capecitabine for Patients Aged ? 70 Years With Locally Advanced Rectal Cancer.
Multiple Sclerosis
Discovery and Lead-Optimization of 4,5-Dihydropyrazoles as Mono-Kinase Selective, Orally Bioavailable and Efficacious Inhibitors of Receptor Interacting Protein 1 (RIP1) Kinase.
Muscle Hypotonia
A neonate with recurrent vomiting and generalized hypotonia diagnosed with a deficiency of dihydropyrimidine dehydrogenase.
Nasopharyngeal Carcinoma
Circadian rhythm in dihydropyrimidine dehydrogenase activity and reduced glutathione content in peripheral blood of nasopharyngeal carcinoma patients.
Nasopharyngeal Carcinoma
Matrix metalloproteinase 1 promotes tumorigenesis and inhibits the sensitivity to 5-fluorouracil of nasopharyngeal carcinoma.
Neoplasm Metastasis
5-Fluorouracil-related gene expression in primary sites and hepatic metastases of colorectal carcinomas.
Neoplasm Metastasis
Analysis of the mRNA Expression Levels of Thymidylate Synthase (TS), Dihydropyrimidine Dehydrogenase (DPD) and Orotate Phosphoribosyl Transferase (OPRT) in Liver Metastases from Colorectal Cancer.
Neoplasm Metastasis
Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis.
Neoplasm Metastasis
Correlation between chemosensitivity and mRNA expression level of 5-fluorouracil-related metabolic enzymes during liver metastasis of colorectal cancer.
Neoplasm Metastasis
Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance.
Neoplasm Metastasis
Dihydropyrimidine dehydrogenase mRNA expression in peripheral blood of rectal cancer patients is significantly associated with residual tumor and distant metastases following resection.
Neoplasm Metastasis
DPYSL2 as potential diagnostic and prognostic biomarker linked to immune infiltration in lung adenocarcinoma.
Neoplasm Metastasis
Effects of UFT on thymidylate synthase and dihydropyrimidine dehydrogenase activities in lung cancer.
Neoplasm Metastasis
Expression of dihydropyrimidine dehydrogenase, orotate phosphoribosyl transferase and thymidylate synthase in patients with primary colorectal cancer, and associations with site of first metastasis.
Neoplasm Metastasis
Expression of thymidylate synthase and dihydropyrimidine dehydrogenase in primary oral squamous cell carcinoma and corresponding metastases in cervical lymph nodes: association with the metastasis suppressor CD82.
Neoplasm Metastasis
K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy.
Neoplasm Metastasis
Predictive molecular markers for colorectal cancer patients with resected liver metastasis and adjuvant chemotherapy.
Neoplasm Metastasis
Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly treated stage III colon cancer patients.
Neoplasm Metastasis
[Antimetastatic and antitumor effects of fluoropyrimidines alone and combined with taxanes in a murine model of breast cancer metastatic to the lung]
Neoplasm Metastasis
[Clinical significance of determinations of dihydropyrimidine dehydrogenase levels in primary and hepatic lesions of colorectal cancer patients]
Neoplasm Metastasis
[Dihydropyrimidine dehydrogenase gene expression in patients with hepatic metastases from colorectal cancer]
Neoplasm Metastasis
[Effect of peroral doxifluridine plus hepatic arterial infusion for synchronous liver metastasis of colorectal cancer--correlation with the expression of thymidine phosphorylase and dihydropyrimidine dehydrogenase in primary colorectal cancer lesions]
Neoplasm Metastasis
[Relationship between the anti-metastatic effect of UFT and in vitro chemosensitivity to 5-FU in metastatic tumors from orthotopic implanted colon cancer in nude rats]
Neoplasm Metastasis
[Results of prophylactic hepatic arterial chemotherapy for liver metastases of Dukes C colorectal cancer--correlation with tumoral expression of dihydropyrimidine dehydrogenase, thymidylate synthase, p53, or orotate phosphoribosyl transferase]
Neoplasm, Residual
Dihydropyrimidine dehydrogenase mRNA expression in peripheral blood of rectal cancer patients is significantly associated with residual tumor and distant metastases following resection.
Neoplasms
5-Fluorouracil-based adjuvant chemotherapy improves the clinical outcomes of patients with lymphovascular invasion of upper urinary tract cancer and low expression of dihydropyrimidine dehydrogenase.
Neoplasms
A fundamental study of regional chemotherapy given by intraarterial infusion with concomitant hemodialysis and hemoperfusion.
Neoplasms
A novel immunotherapeutic modality with direct hemoperfusion targeting transforming growth factor-beta prolongs the survival of tumor-bearing rats.
Neoplasms
A Phase I study of weekly intravenous oxaliplatin in combination with oral daily capecitabine and radiation therapy in the neoadjuvant treatment of rectal adenocarcinoma.
Neoplasms
A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: the mechanism for tumor-selective accumulation of 5-FU.
Neoplasms
A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil.
Neoplasms
A Simple Glutathione-Responsive Turn-On Theranostic Nanoparticle for Dual-Modal Imaging and Chemo-Photothermal Combination Therapy.
Neoplasms
Activator protein accelerates dihydropyrimidine dehydrogenase gene transcription in cancer cells.
Neoplasms
Administration of adjuvant oral tegafur/uracil chemotherapy post hepatocellular carcinoma resection: A randomized controlled trial.
Neoplasms
Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals.
Neoplasms
Antimetastatic and anticancer activity of S-1, a new oral dihydropyrimidine-dehydrogenase-inhibiting fluoropyrimidine, alone and in combination with paclitaxel in an orthotopically implanted human breast cancer model.
Neoplasms
Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models.
Neoplasms
Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects.
Neoplasms
Assessment of plasma uracil-to-dihydrouracil concentration ratio as an indicator of dihydropyrimidine dehydrogenase activity in clinically normal dogs and dogs with neoplasia or renal insufficiency.
Neoplasms
Association and prediction of severe 5-fluorouracil toxicity with dihydropyrimidine dehydrogenase gene polymorphisms: A meta-analysis.
Neoplasms
Augmentation of the antitumor activity of capecitabine by a tumor selective dihydropyrimidine dehydrogenase inhibitor, RO0094889.
Neoplasms
Biochemical modulation of 5-fluorouacil through dihydropyrimidine dehydrogenase inhibition: a Southwest Oncology Group phase II trial of eniluracil and 5-fluorouracil in advanced resistant colorectal cancer.
Neoplasms
Biopsy specimen microvessel density is a useful prognostic marker in patients with T(2-4)M(0) esophageal cancer treated with chemoradiotherapy.
Neoplasms
Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.
Neoplasms
Changes in thymidylate synthase and its inhibition rate and changes in dihydropyrimidine dehydrogenase after the administration of 5-fluorouracil with cisplatin to nude mice with gastric cancer xenograft SC-1-NU.
Neoplasms
Changes to the dihydropyrimidine dehydrogenase gene copy number influence the susceptibility of cancers to 5-FU-based drugs: Data mining of the NCI-DTP data sets and validation with human tumour xenografts.
Neoplasms
Characterization of a rare nonpathogenic sequence variant (c.1905C>T) of the dihydropyrimidine dehydrogenase gene (DPYD).
Neoplasms
Chemotherapy-induced necrotising tumour lysis and perforation of a huge gastric cancer simulating emphysematous pancreatitis.
Neoplasms
Clinical application of immunoreactivity of dihydropyrimidine dehydrogenase (DPD) in gastric scirrhous carcinoma treated with S-1, a new DPD inhibitory fluoropyrimidine.
Neoplasms
Clinical implications of immunoreactivity of thymidylate synthase and dihydropyrimidine dehydrogenase in gastric cancer treated with oral fluoropyrimidine (S-1). Study Group of S-1 for Gastric Cancer.
Neoplasms
Clinical significance of thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in transitional cell cancer.
Neoplasms
Co-inhibition of cyclooxygenase-2 and dihydropyrimidine dehydrogenase by non-steroidal anti-inflammatory drugs in tumor cells and xenografts.
Neoplasms
Combination chemotherapy with S-1 and platinum in advanced hepatocellular carcinoma.
Neoplasms
Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer.
Neoplasms
Combination of oral fluoropyrimidine and docetaxel: reappraisal of synergistic effect against gastric carcinoma xenografts.
Neoplasms
Combined evaluation of dihydropyrimidine dehydrogenase and thymidine phosphorylate mRNA levels in tumor predicts the histopathological effect of 5-fluorouracil-based chemoradiotherapy.
Neoplasms
Combining metabolomics with bioanalysis methods to investigate the potential toxicity of dihexyl phthalate.
Neoplasms
Comparative analysis of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in colorectal cancer and surrounding normal tissue.
Neoplasms
Comparison of dihydropyrimidine dehydrogenase from human, rat, pig and cow liver. Biochemical and immunological properties.
Neoplasms
Complete inhibition of anisomycin and UV radiation but not cytokine induced JNK and p38 activation by an aryl-substituted dihydropyrrolopyrazole quinoline and mixed lineage kinase 7 small interfering RNA.
Neoplasms
Construction of possible integrated predictive index based on EGFR and ANXA3 polymorphisms for chemotherapy response in fluoropyrimidine-treated Japanese gastric cancer patients using a bioinformatic method.
Neoplasms
Contribution of dihydropyrimidinase gene alterations to the development of serious toxicity in fluoropyrimidine-treated cancer patients.
Neoplasms
Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients.
Neoplasms
Correlations between antitumor activities of fluoropyrimidines and DPD activity in lung tumor xenografts.
Neoplasms
Correlations of Clinicopathological Factors with Protein Expression Levels of Thymidylate Synthase, Dihydropyrimidine Dehydrogenase and Orotate Phosphoribosyltransferase in Colorectal Cancer.
Neoplasms
Cytotoxic effect of some 1, 4-dihydropyridine derivatives containing nitroimidazole moiety.
Neoplasms
Cytotoxic response of 5-fluorouracil-resistant cells to gene- and cell-directed enzyme/prodrug treatment.
Neoplasms
Deficient expression of the DPD gene is caused by epigenetic modification in biliary tract cancer cells, and induces high sensitivity to 5-FU treatment.
Neoplasms
Detailed analysis of five mutations in dihydropyrimidine dehydrogenase detected in cancer patients with 5-fluorouracil-related side effects.
Neoplasms
Determination of thymidine phosphorylase expression level facilitates recurrence risk stratification in stage II/III colorectal cancer following adjuvant chemotherapy with oral fluoropyrimidines.
Neoplasms
Development and use of a flexible data harmonization platform to facilitate the harmonization of individual patient data for meta-analyses.
Neoplasms
Development of new promising antimetabolite, DFP-11207 with self-controlled toxicity in rodents.
Neoplasms
Differential effects of two fluorouracil administration regimens for colorectal cancer.
Neoplasms
Dihydropyrimidinase protects from DNA replication stress caused by cytotoxic metabolites.
Neoplasms
Dihydropyrimidine Dehydrogenase 85T>C Mutation Is Associated With Ocular Toxicity of 5-Fluorouracil: A Case Report.
Neoplasms
Dihydropyrimidine dehydrogenase activity and messenger RNA level may be related to the antitumor effect of 5-fluorouracil on human tumor xenografts in nude mice.
Neoplasms
Dihydropyrimidine dehydrogenase activity and thymidylate synthase level are associated with response to 5-fluorouracil in human colorectal cancer.
Neoplasms
Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma: implication in 5-fluorouracil-based chemotherapy.
Neoplasms
Dihydropyrimidine dehydrogenase activity in normal, inflammatory and tumour tissues of colon and liver in humans.
Neoplasms
Dihydropyrimidine dehydrogenase activity of cancerous and non-cancerous tissues in liver and large intestine.
Neoplasms
Dihydropyrimidine dehydrogenase and messenger RNA levels in gastric cancer: possible predictor for sensitivity to 5-fluorouracil.
Neoplasms
Dihydropyrimidine dehydrogenase and orotate phosphoribosyltransferase in esophageal cancer patients: Correlation with clinicopathological factors and prognosis.
Neoplasms
Dihydropyrimidine dehydrogenase and thymidylate synthase activities in hepatocellular carcinomas and in diseased livers.
Neoplasms
DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY (DPD) IN GI MALIGNANCIES: EXPERIENCE OF 4-YEARS.
Neoplasms
Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy.
Neoplasms
Dihydropyrimidine dehydrogenase enzyme deficiency: clinical and genetic assessment of prevalence in Turkish cancer patients.
Neoplasms
Dihydropyrimidine dehydrogenase in livers from mouse and rat, and in human liver, colon tumors, and mucosa in relation to anabolism of 5-fluorouracil.
Neoplasms
Dihydropyrimidine dehydrogenase mRNA level correlates with the response to 5-fluorouracil-based chemo-immuno-radiation therapy in human oral squamous cell cancer.
Neoplasms
Dihydropyrimidine dehydrogenase: its role in 5-fluorouracil clinical toxicity and tumor resistance.
Neoplasms
Discrepancies between the gene expression, protein expression, and enzymatic activity of thymidylate synthase and dihydropyrimidine dehydrogenase in human gastrointestinal cancers and adjacent normal mucosa.
Neoplasms
Double-loop hairpin probe and doxorubicin-loaded gold nanoparticles for the ultrasensitive electrochemical sensing of microRNA.
Neoplasms
Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer.
Neoplasms
DPYSL2 as potential diagnostic and prognostic biomarker linked to immune infiltration in lung adenocarcinoma.
Neoplasms
Effects of UFT on thymidylate synthase and dihydropyrimidine dehydrogenase activities in lung cancer.
Neoplasms
Efficacy of laser capture microdissection plus RT-PCR technique in analyzing gene expression levels in human gastric cancer and colon cancer.
Neoplasms
Elevated levels of mRNAs encoding dihydropyrimidine dehydrogenase and thymidylate synthase are associated with improved survival of patients with hepatocellular carcinoma treated with S-1.
Neoplasms
Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells.
Neoplasms
Enhancing 5-fluorouracil cytotoxicity by inhibiting dihydropyrimidine dehydrogenase activity with uracil in human tumor cells.
Neoplasms
Estimation of dihydropyrimidine dehydrogenase activity: does it have a role in cancer therapy?
Neoplasms
Evaluation of 5-fluorouracil metabolic enzymes as predictors of response to adjuvant chemotherapy outcomes in patients with stage II/III colorectal cancer: a decision-curve analysis.
Neoplasms
Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues.
Neoplasms
Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer.
Neoplasms
Expression of dihydropyrimidine dehydrogenase in cancer cells but not in stromal cells predicts the efficacy of fluorouracil treatment in patients with gastric carcinoma.
Neoplasms
Expression of dihydropyrimidine dehydrogenase, thymidylate synthase, p53 and p21 in metastatic liver tumor from colorectal cancer after 5-fluorouracil-based chemotherapy.
Neoplasms
Expression of thymidylate synthase, orotate phosphoribosyltransferase and dihydropyrimidine dehydrogenase in thymic epithelial tumors.
Neoplasms
Factors predicting the response to oral fluoropyrimidine drugs: a phase II trial on the individualization of postoperative adjuvant chemotherapy using oral fluorinated pyrimidines in stage III colorectal cancer treated by curative resection (ACT-01 Study).
Neoplasms
Force Field Parameters for Fe2+4S2-4 Clusters of Dihydropyrimidine Dehydrogenase, the 5-Fluorouracil Cancer Drug Deactivation Protein: A Step towards In Silico Pharmacogenomics Studies.
Neoplasms
Future prospects of personalized chemotherapy in gastric cancer patients: results of a prospective randomized pilot study.
Neoplasms
Gene expression analysis using human cancer xenografts to identify novel predictive marker genes for the efficacy of 5-fluorouracil-based drugs.
Neoplasms
Gene expression of 5-fluorouracil metabolic enzymes in primary gastric cancer: correlation with drug sensitivity against 5-fluorouracil.
Neoplasms
Genetic variation in dihydropyrimidine dehydrogenase (DPYD) gene in a healthy adult Indian population.
Neoplasms
Germline mutation of dihydropyrimidine dehydrogenese gene among a Japanese population in relation to toxicity to 5-Fluorouracil.
Neoplasms
Gimeracil sensitizes cells to radiation via inhibition of homologous recombination.
Neoplasms
High Ki67, Bax, and thymidylate synthase expression well correlates with response to chemoradiation therapy in locally advanced rectal cancers: proposal of a logistic model for prediction.
Neoplasms
High-grade and hormone-treated prostate cancer express high levels of thymidylate synthase.
Neoplasms
High-performance liquid chromatographic assay with UV detection for measurement of dihydrouracil/uracil ratio in plasma.
Neoplasms
High-resolution melting analysis of the common c.1905+1G>A mutation causing dihydropyrimidine dehydrogenase deficiency and lethal 5-fluorouracil toxicity.
Neoplasms
Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluororuacil based chemotherapy.
Neoplasms
Immunohistochemical analysis of thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer (cUICC II/III): correlation with histopathologic tumor regression after 5-fluorouracil-based long-term neoadjuvant chemoradiotherapy.
Neoplasms
Immunohistochemical dihydropyrimidine dehydrogenase expression is a good prognostic indicator for patients with Dukes' C colorectal cancer.
Neoplasms
Impact of dihydropyrimidine dehydrogenase on 5-fluorouracil treatment in cancer patients.
Neoplasms
Impacts of fluorouracil-metabolizing enzymes on the outcomes of patients treated with S-1 alone or S-1 plus cisplatin for first-line treatment of advanced gastric cancer.
Neoplasms
In vivo effect of 5-ethynyluracil on 5-fluorouracil metabolism determined by 19F nuclear magnetic resonance spectroscopy.
Neoplasms
Inhibition of dihydropyrimidine dehydrogenase by alpha-interferon: experimental data on human tumor cell lines.
Neoplasms
Inhibitors of C1q biosynthesis suppress activation of murine macrophages for both antibody-independent and antibody-dependent tumor cytotoxicity.
Neoplasms
Interleukin-2 as a modulator of 5-fluorouracil in hepatic arterial immunochemotherapy for liver metastases.
Neoplasms
Intratumor dihydropyrimidine dehydrogenase mRNA expression levels are decreased in extramammary Paget's disease.
Neoplasms
Intratumoral dihydropyrimidine dehydrogenase messenger RNA level reflects tumor progression in human colorectal cancer.
Neoplasms
Intratumoural thymidylate synthase and dihydropyrimidine dehydrogenase activities are good predictors of 5-fluorouracil sensitivity in colorectal cancer.
Neoplasms
Investigation of IVS14+ 1G > A polymorphism of DPYD gene in a group of Turkish patients with colorectal cancer.
Neoplasms
Is capecitabine safe in patients with gastrointestinal cancer and dihydropyrimidine dehydrogenase deficiency?
Neoplasms
K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy.
Neoplasms
Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients.
Neoplasms
Logistic regression model of the clinical response to 5-fluorouracil based chemotherapy for metastatic colorectal cancer patients.
Neoplasms
Long-term survival on capecitabine in two gemcitabine refractory pancreatic cancer patients. Is there a pharmacogenetic explanation?
Neoplasms
Low Incidence of the DPD IVS14+1G>A Polymorphism in Jordanian Breast and Colorectal Cancer patients
Neoplasms
Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients.
Neoplasms
Microsatellite instability in colorectal cancer and association with thymidylate synthase and dihydropyrimidine dehydrogenase expression.
Neoplasms
Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging of drug action.
Neoplasms
Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity.
Neoplasms
Molecular factors of 5-fluorouracil metabolism in colorectal cancer: analysis of primary tumor and lymph node metastasis.
Neoplasms
Mutations in exon 14 of dihydropyrimidine dehydrogenase and 5-Fluorouracil toxicity in Portuguese colorectal cancer patients.
Neoplasms
Nab-Paclitaxel Plus S-1 Shows Increased Antitumor Activity in Patient-Derived Pancreatic Cancer Xenograft Mouse Models.
Neoplasms
New Challenges and Inspired Answers for Anticancer Drug Discovery and Development.
Neoplasms
Novel single nucleotide polymorphisms of the dihydropyrimidinase gene (DPYS) in Japanese individuals.
Neoplasms
Overexpression of LRP12, a gene contained within an 8q22 amplicon identified by high-resolution array CGH analysis of oral squamous cell carcinomas.
Neoplasms
Paclitaxel, carboplatin, 5-fluorouracil, and radiation for locally advanced esophageal cancer: phase II results of preliminary pharmacologic and molecular efforts to mitigate toxicity and predict outcomes: North Central Cancer Treatment Group (N0044).
Neoplasms
Pharmacokinetic and Pharmacodynamic Analyses of 5-Fluorouracil in East-Asian Patients with Nasopharyngeal Carcinoma.
Neoplasms
Pharmacokinetic/pharmacodynamic modeling of 5-fluorouracil by using a biomarker to predict tumor growth in a rat model of colorectal cancer.
Neoplasms
Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies.
Neoplasms
Pharmacokinetics of 5-fluorouracil in elderly Japanese cancer patients treated with S-1 (a combination of tegafur and dihydropyrimidine dehydrogenase inhibitor 5-chloro-2,4-dihydroxypyridine).
Neoplasms
Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome.
Neoplasms
Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study.
Neoplasms
Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a gynecologic oncology group study.
Neoplasms
Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylase.
Neoplasms
Phase II trial of capecitabine and weekly docetaxel for metastatic castrate resistant prostate cancer.
Neoplasms
Polymorphism of dihydropyrimidine dehydrogenase (DPYD) Cys29Arg and risk of six malignancies in Japanese.
Neoplasms
Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy.
Neoplasms
Population study of expression of thymidylate synthase and dihydropyrimidine dehydrogenase in patients with solid tumors.
Neoplasms
Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts.
Neoplasms
Potential importance of dihydropyrimidine dehydrogenase (DPD) in cancer chemotherapy.
Neoplasms
Predicting 5-FU sensitivity using human colorectal cancer specimens: comparison of tumor dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase activities with in vitro chemosensitivity to 5-FU.
Neoplasms
Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer.
Neoplasms
Predictive molecular markers for colorectal cancer patients with resected liver metastasis and adjuvant chemotherapy.
Neoplasms
Predictive value of dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (Tegafur + Uracil) in patients with p-stage I nonsmall-cell lung cancer.
Neoplasms
Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (tegafur+uracil) in patients with non-small cell lung cancer.
Neoplasms
Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly treated stage III colon cancer patients.
Neoplasms
Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy.
Neoplasms
Prognostic significance of dihydropyrimidine dehydrogenase expression in breast cancer.
Neoplasms
Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy.
Neoplasms
Prognostic significance of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in biliary tract cancer patients receiving adjuvant 5-fluorouracil-based chemotherapy.
Neoplasms
Prognostic value of histologic tumor regression, thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer UICC Stage II/III after neoadjuvant chemoradiotherapy.
Neoplasms
Prophylactic activity of dihydroheptaprenol, a synthetic polyprenol derivative, against Sendai virus infection in mice.
Neoplasms
Pyrimidine base degradation in cultured murine C-1300 neuroblastoma cells and in situ tumors.
Neoplasms
Quantitation of dihydropyrimidine dehydrogenase (DPD) mRNA expression levels in normal colon and colorectal cancer tumor paraffin-embedded tissue specimens.
Neoplasms
Randomized clinical trial of adjuvant chemotherapy with S-1 versus gemcitabine after pancreatic cancer resection.
Neoplasms
Rapid gas chromatographic-mass spectrometric diagnosis of dihydropyrimidine dehydrogenase deficiency and dihydropyrimidinase deficiency.
Neoplasms
Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test.
Neoplasms
Real-time RT-PCR (TaqMan) of tumor mRNA to predict sensitivity of specimens to 5-fluorouracil.
Neoplasms
Regulation of dihydropyrimidine dehydrogenase and pyrimidine nucleoside phosphorylase activities by growth factors and subsequent effects on 5-fluorouracil sensitivity in tumor cells.
Neoplasms
Regulation of genes of the circadian clock in human colon cancer: reduced period-1 and dihydropyrimidine dehydrogenase transcription correlates in high-grade tumors.
Neoplasms
Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients.
Neoplasms
Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion.
Neoplasms
Relationship between expression of 5-fluorouracil metabolic enzymes and 5-fluorouracil sensitivity in esophageal carcinoma cell lines.
Neoplasms
Relationship between protein levels and gene expression of dihydropyrimidine dehydrogenase in human tumor cells during growth in culture and in nude mice.
Neoplasms
Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity.
Neoplasms
Reversal of multidrug resistance in cancer cells by novel asymmetrical 1,4-dihydropyridines.
Neoplasms
Role of dihydropyrimidine dehydrogenase and thymidylate synthase expression in immunohistochemistry of intrahepatic cholangiocarcinoma.
Neoplasms
Role of dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine against non-small cell lung cancer--in correlation with the tumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase.
Neoplasms
Role of thymidine phosphorylase and dihydropyrimidine dehydrogenase in tumour progression and sensitivity to doxifluridine in gastric cancer patients.
Neoplasms
Roles of thymidylate synthase and dihydropyrimidine dehydrogenase expression in blood as predictors of response to multimodal therapy in esophageal cancer.
Neoplasms
Roles of thymidylate synthase and dihydropyrimidine dehydrogenase in tumor progression and sensitivity to 5-fluorouracil in human gastric cancer.
Neoplasms
Screening of dihydropyrimidine dehydrogenase genetic variants by direct sequencing in different ethnic groups.
Neoplasms
Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity.
Neoplasms
Severe colitis after administration of UFT chemotherapy for temporal bone carcinoma.
Neoplasms
Single ascending dose tolerability, pharmacokinetic-pharmacodynamic study of dihydropyrimidine dehydrogenase inhibitor Ro 09-4889.
Neoplasms
Somatic copy number changes in DPYD are associated with lower risk of recurrence in triple-negative breast cancers.
Neoplasms
SphK2 confers 5-fluorouracil resistance to colorectal cancer via upregulating H3K56ac-mediated DPD expression.
Neoplasms
Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients.
Neoplasms
Superior antitumour activity of S-1 in tumours with a high dihydropyrimidine dehydrogenase activity.
Neoplasms
The activities of thymidine phosphorylase and dihydropyrimidine dehydrogenase in colorectal cancer depend on where the sample is taken.
Neoplasms
The combination of hyperthermia or chemotherapy with gimeracil for effective radiosensitization.
Neoplasms
The effect of chemotherapy or radiotherapy on thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in cancer of the uterine cervix.
Neoplasms
The effect of L-3, 4-dehydroproline on the antitumor activity and toxicity of bleomycin.
Neoplasms
The expression profiles of orotate phosphoribosyltransferase and dihydropyrimidine dehydrogenase in gastric cancer and their clinical significance.
Neoplasms
The prognostic significance of thymidine phosphorylase, thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expressions in breast carcinomas.
Neoplasms
The ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase in tumour tissues of patients with metastatic gastric cancer is predictive of the clinical response to 5'-deoxy-5-fluorouridine.
Neoplasms
The Role of Dihydropyrimidine Dehydrogenase and Thymidylate Synthase Polymorphisms in Fluoropyrimidine-Based Cancer Chemotherapy in an Iranian Population.
Neoplasms
The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil.
Neoplasms
The upregulation of dihydropyrimidine dehydrogenase in liver is involved in acquired resistance to 5-fluorouracil.
Neoplasms
Thymidine kinase, thymidylate synthase, and dihydropyrimidine dehydrogenase profiles of cell lines of the National Cancer Institute's Anticancer Drug Screen.
Neoplasms
Thymidine phosphorylase affects clinical outcome following surgery and mRNA expression levels of four key enzymes for 5-fluorouracil metabolism in patients with stage I and II non-small cell lung cancer.
Neoplasms
Thymidine phosphorylase and dihydropyrimidine dehydrogenase activity in colorectal carcinoma and patients prognosis.
Neoplasms
Thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in hepatocellular carcinoma and metastatic liver cancer.
Neoplasms
Thymidine phosphorylase and dihydropyrimidine dehydrogenase expression levels in tumor and normal tissue specimens of t3 human colorectal carcinoma.
Neoplasms
Thymidine phosphorylase expression is preserved after radiotherapy in patients with cervical squamous cell carcinoma.
Neoplasms
Thymidine phosphorylase mRNA level predicts survival of patients with advanced oropharyngeal cancer.
Neoplasms
Thymidine phosphorylase to dihydropyrimidine dehydrogenase ratio as a predictive factor of response to preoperative chemoradiation with capecitabine in patients with advanced rectal cancer.
Neoplasms
Thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expression in primary colorectal tumors-correlation to tumor histopathology and clinical follow-up.
Neoplasms
Thymidylate synthase and dihydropyrimidine dehydrogenase activities in non-small cell lung cancer tissues: relationship with in vitro sensitivity to 5-fluorouracil.
Neoplasms
Thymidylate synthase and dihydropyrimidine dehydrogenase are upregulated in pancreatic and biliary tract cancers.
Neoplasms
Thymidylate synthase and dihydropyrimidine dehydrogenase expression levels are associated with response to S-1 plus carboplatin in advanced non-small cell lung cancer.
Neoplasms
Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in relation to differentiation of gastric cancer.
Neoplasms
Thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer: relationship between mRNA expression and activity.
Neoplasms
Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression after administration of 5-fluorouracil to patients with colorectal cancer.
Neoplasms
Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA levels in tumor tissues and the efficacy of 5-fluorouracil in patients with non-small-cell lung cancer.
Neoplasms
Thymidylate synthase expression and activity: relation to S-phase parameters and 5-fluorouracil sensitivity.
Neoplasms
Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexed.
Neoplasms
Thymidylate synthase gene expression in primary tumors predicts activity of s-1-based chemotherapy for advanced gastric cancer.
Neoplasms
Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine.
Neoplasms
Thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase mRNA and protein expression levels in solid tumors in large scale population analysis.
Neoplasms
Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression, and histological tumour regression after 5-FU-based neo-adjuvant chemoradiotherapy in rectal cancer.
Neoplasms
Thymidylate synthetase and dihydropyrimidine dehydrogenase levels in gastric cancer.
Neoplasms
Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics.
Neoplasms
Tumor 5-FU-related mRNA Expression and Efficacy of Oral Fluoropyrimidines in Adjuvant Chemotherapy of Colorectal Cancer.
Neoplasms
Tumor dihydropyrimidine dehydrogenase expression is a useful marker in adjuvant therapy with oral fluoropyrimidines after curative resection of colorectal cancer.
Neoplasms
Tumor dihydropyrimidine dehydrogenase in stage II and III colorectal cancer: low level expression is a beneficial marker in oral-adjuvant chemotherapy, but is also a predictor for poor prognosis in patients treated with curative surgery alone.
Neoplasms
Up-regulation in dihydropyrimidine dehydrogenase activity by raltitrexed causes antagonism in combination with 5-fluorouracil.
Neoplasms
Where should the specimen be excised for the chemosensitivity of colorectal cancer to 5-fluorouracil?
Neoplasms
[A case of uterine cervical cancer in which UFT was an effective preoperative treatment]
Neoplasms
[A complete response after neoadjuvant chemotherapy for advanced gastric cancer with esophageal invasion]
Neoplasms
[A new strategy for malignancies by direct hemoperfusion using bacterial endotoxin bounded fiber]
Neoplasms
[Antimetastatic and antitumor effects of fluoropyrimidines alone and combined with taxanes in a murine model of breast cancer metastatic to the lung]
Neoplasms
[Clinical significance of determinations of dihydropyrimidine dehydrogenase levels in primary and hepatic lesions of colorectal cancer patients]
Neoplasms
[Clinicopathological significance of pyrimidine nucleoside phosphorylase (PyNPase) and dihydropyrimidine dehydrogenase (DPD) in advanced colorectal cancer]
Neoplasms
[Comparison of the efficacy and safety of capecitabine or tegafur, gimeracil and oteracil potassium capsules combined with oxaliplatin chemotherapy regimens in the treatment of advanced gastric cancer].
Neoplasms
[Dihydropyrimidine dehydrogenase activity in urothelial cancer--influence of UFT administration on DPD activity]
Neoplasms
[Evaluation of chemosensitivity testing by CD-DST, and TS and DPD activity in cases of colorectal liver]
Neoplasms
[Expression of dihydropyrimidine dehydrogenase in primary colorectal cancer and liver metastasis--a relationship between mRNA levels in cancer cells and protein levels in cancerous tissue and effect of 5-fluorouracil]
Neoplasms
[Expression of metabolic enzymes of fluoropyrimidines in primary colorectal cancer and its clinical significance]
Neoplasms
[Expression of recombinant human dihydropyrimidine dehydrogenase and its application to the preparation of anti-DPD antibodies for immunochemical detection]
Neoplasms
[Hepatic recurrence after prophylactic hepatic arterial infusion of 5-fluorouracil for Dukes' C colorectal cancer--correlation with the expression of dihydropyrimidine dehydrogenase in the primary tumor]
Neoplasms
[Human tumor sensitivity to 5-fluorouracil influenced by dihydropyrimidine dehydrogenase mRNA in the tumor]
Neoplasms
[Influence on 5-fluorouracil metabolism by combination of interferon-alpha and 5-fluorouracil against human hepatocellular carcinoma xenografts]
Neoplasms
[Mutations in the dihydropyrimidine dehydrogenase gene and their role in 5-fluororuracil intolerance]
Neoplasms
[Selection of anticancer drug for poorly-differentiated adenocarcinoma of colorectum from the level of orotate phosphoribosyl transferase and dihydropyrimidine dehydrogenase activities in cancer tissue]
Neoplasms
[Severe bone marrow suppression during adjuvant chemotherapy for gastric cancer by S-1 and its possible relationship to dihydropyrimidine dehydrogenase deficiency]
Neoplasms
[The Relationship between the efficacy of mFOLFOX6 treatment and the expression of TS, DPD, TP, and ERCC-1 in unresectable colorectal cancer].
Neoplasms
[Thymidylate synthase and dihydropyrimidine dehydrogenase activity in a metastatic liver tumor from colorectal cancer]
Neoplasms
[Thymidylate synthase and dihydropyrimidine dehydrogenase expression and histological effects of preoperative UFT in gastric cancer patients]
Neoplasms
[Thymidylate synthase and dihydropyrimidine dehydrogenase gene expressions in colorectal cancer using the Danenberg tumor profile method]
Neoplasms
[Thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in soft-tissue sarcoma versus capecitabine potential]
Neoplasms
¹?F-FDG uptake on PET is a predictive marker of thymidylate synthase expression in patients with thoracic neoplasms.
Neoplasms, Squamous Cell
Dihydropyrimidine dehydrogenase mRNA level correlates with the response to 5-fluorouracil-based chemo-immuno-radiation therapy in human oral squamous cell cancer.
Neoplasms, Squamous Cell
Thymidine phosphorylase expression is preserved after radiotherapy in patients with cervical squamous cell carcinoma.
Neuroblastoma
Correlations of dihydropyrimidine dehydrogenase, thymidine phosphorylase and thymidine kinase activities in strongly and weakly malignant cultured murine neuroblastoma cells.
Neuroblastoma
Pyrimidine base degradation in cultured murine C-1300 neuroblastoma cells and in situ tumors.
Neuromuscular Diseases
Psychometric properties of the Duke Health Profile in a neuromuscular disease population.
Neutropenia
Cost-effectiveness of screening for DPYD polymorphisms to prevent neutropenia in cancer patients treated with fluoropyrimidines.
Neutropenia
Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation.
Neutropenia
Topical application of 5-fluorouracil 5 percent cream associated with severe neutropenia: discussion of a case and review of systemic reactions after topical treatment with 5-fluorouracil.
Nystagmus, Pathologic
Clinical and VNG Features in Anterior Canal BPPV-An Analysis of 13 Cases.
ornithine carbamoyltransferase deficiency
Rapid screening of high-risk patients for disorders of purine and pyrimidine metabolism using HPLC-electrospray tandem mass spectrometry of liquid urine or urine-soaked filter paper strips.
Ornithine Carbamoyltransferase Deficiency Disease
Rapid screening of high-risk patients for disorders of purine and pyrimidine metabolism using HPLC-electrospray tandem mass spectrometry of liquid urine or urine-soaked filter paper strips.
Osteogenesis Imperfecta
Severe 5-fluorouracil toxicity possibly secondary to dihydropyrimidine dehydrogenase deficiency in a breast cancer patient with osteogenesis imperfecta.
Osteogenesis Imperfecta
[Post-surgery radiation therapy for a patient with osteogenesis imperfecta: About one case].
Ovarian Neoplasms
A Turn-On Detection of DNA Sequences by Means of Fluorescence of DNA-Templated Silver Nanoclusters via Unique Interactions of a Hydrated Ionic Liquid.
Ovarian Neoplasms
Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study.
Ovarian Neoplasms
[Significance of tissue thymidine phosphorylase and dihydropyrimidine dehydrogenase activities in ovarian cancer]
Paget Disease, Extramammary
Intratumor dihydropyrimidine dehydrogenase mRNA expression levels are decreased in extramammary Paget's disease.
Pancreatic Neoplasms
Cardiotoxicity of 5-fluorouracil and capecitabine in a pancreatic cancer patient with a novel mutation in the dihydropyrimidine dehydrogenase gene.
Pancreatic Neoplasms
Clinical implications of dihydropyrimidine dehydrogenase expression in patients with pancreatic cancer who undergo curative resection with S-1 adjuvant chemotherapy.
Pancreatic Neoplasms
Clinical significance of dihydropyrimidine dehydrogenase and thymidylate synthase expression in patients with pancreatic cancer.
Pancreatic Neoplasms
Clinical significance of dihydropyrimidine dehydrogenase in adjuvant 5-fluorouracil liver perfusion chemotherapy for pancreatic cancer.
Pancreatic Neoplasms
Combined Analyses of hENT1, TS, and DPD Predict Outcomes of Borderline-resectable Pancreatic Cancer.
Pancreatic Neoplasms
Contribution of thymidylate synthase to gemcitabine therapy for advanced pancreatic cancer.
Pancreatic Neoplasms
Dihydropyrimidine dehydrogenase activity in human pancreatic tumor tissues.
Pancreatic Neoplasms
Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer.
Pancreatic Neoplasms
High intratumoral dihydropyrimidine dehydrogenase mRNA levels in pancreatic cancer associated with a high rate of response to S-1.
Pancreatic Neoplasms
Impact of dihydropyrimidine dehydrogenase and ?-glutamyl hydrolase on the outcomes of patients treated with gemcitabine or S-1 as adjuvant chemotherapy for advanced pancreatic cancer.
Pancreatic Neoplasms
Long-term survival on capecitabine in two gemcitabine refractory pancreatic cancer patients. Is there a pharmacogenetic explanation?
Pancreatic Neoplasms
Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome.
Pancreatic Neoplasms
Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylase.
Pancreatic Neoplasms
Role of thymidine phosphorylase and orotate phosphoribosyltransferase mRNA expression and its ratio to dihydropyrimidine dehydrogenase in the prognosis and clinicopathological features of patients with pancreatic cancer.
Pancreatic Neoplasms
[The thymidine phosphorylase to dihydropyrimidine dehydrogenase ratio in pancreatic cancer]
Paralysis
Genotype-phenotype correlations of DHP receptor alpha 1-subunit gene mutations causing hypokalemic periodic paralysis.
Paralysis
Mutation in DHP receptor alpha 1 subunit (CACLN1A3) gene in a Dutch family with hypokalaemic periodic paralysis.
Paralysis
Regulation of dihydropyridine and ryanodine receptor gene expression in skeletal muscle. Role of nerve, protein kinase C, and cAMP pathways.
Paralysis
Skeletal muscle DHP receptor mutations alter calcium currents in human hypokalaemic periodic paralysis myotubes.
Penile Neoplasms
[Expression of thymidylate synthase and dihydropyrimidine dehydrogenase in penile cancer].
Pneumonia
Kinetic characterization of the WalRKSpn (VicRK) two-component system of Streptococcus pneumoniae: dependence of WalKSpn (VicK) phosphatase activity on its PAS domain.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
DPYD gene polymorphisms are associated with risk and chemotherapy prognosis in pediatric patients with acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Letter regarding Zhao et al. entitled " DPYD gene polymorphisms are associated with risk and chemotherapy prognosis in pediatric patients with acute lymphoblastic leukemia".
Prediabetic State
Evaluation of the diabetes health plan to improve diabetes care and prevention.
Pressure Ulcer
Is Health-Related Quality of Life an Independent Prognostic Factor For 12-Month Mortality and Nursing Home Placement among Elderly Patients Hospitalized via the Emergency Department?
Prostatic Neoplasms
Expression of thymidylate synthase, dihydropyrimidine dehydrogenase, thymidine phosphorylase, and orotate phosphoribosyl transferase in prostate cancer.
Prostatic Neoplasms
The significance of the expression of dihydropyrimidine dehydrogenase in prostate cancer.
Pulmonary Fibrosis
Ability to Suppress TGF-?-Activated Myofibroblast Differentiation Distinguishes the Anti-pulmonary Fibrosis Efficacy of Two Danshen-Containing Chinese Herbal Medicine Prescriptions.
purine-nucleoside phosphorylase deficiency
Rapid screening of high-risk patients for disorders of purine and pyrimidine metabolism using HPLC-electrospray tandem mass spectrometry of liquid urine or urine-soaked filter paper strips.
purine-nucleoside phosphorylase deficiency
Thirteen years experience with selective screening for disorders in purine and pyrimidine metabolism.
Rectal Neoplasms
Dihydropyrimidine dehydrogenase mRNA expression in peripheral blood of rectal cancer patients is significantly associated with residual tumor and distant metastases following resection.
Rectal Neoplasms
Immunohistochemical analysis of thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer (cUICC II/III): correlation with histopathologic tumor regression after 5-fluorouracil-based long-term neoadjuvant chemoradiotherapy.
Rectal Neoplasms
Immunohistochemical Markers as Predictors of Histopathologic Response and Prognosis in Rectal Cancer Treated with Preoperative Adjuvant Therapy: State of the Art.
Rectal Neoplasms
Importance of thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase expression at the invasive front of T3 rectal cancer as prognostic factors.
Rectal Neoplasms
Prognostic value of histologic tumor regression, thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer UICC Stage II/III after neoadjuvant chemoradiotherapy.
Rectal Neoplasms
The usefulness of immunohistochemical evaluation of dihydropyrimidine dehydrogenase for rectal cancer treated with preoperative radiotherapy.
Rectal Neoplasms
Thymidine phosphorylase to dihydropyrimidine dehydrogenase ratio as a predictive factor of response to preoperative chemoradiation with capecitabine in patients with advanced rectal cancer.
Rectal Neoplasms
Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression, and histological tumour regression after 5-FU-based neo-adjuvant chemoradiotherapy in rectal cancer.
Rectal Neoplasms
Upregulation of thymidine phosphorylase in rectal cancer tissues by mitomycin C.
Rectal Neoplasms
[A case of good response in a rectal cancer patient with decreased dihydropyrimidine dehydrogenase activity because of strict control of the 5-fluorouracil dose].
Renal Insufficiency
Assessment of plasma uracil-to-dihydrouracil concentration ratio as an indicator of dihydropyrimidine dehydrogenase activity in clinically normal dogs and dogs with neoplasia or renal insufficiency.
Renal Insufficiency
[Successful treatment of high-dose methotrexate-induced oliguric acute renal failure by using a combination of hemodialysis filtration and direct hemoperfusion].
Retinitis Pigmentosa
Discovery and Lead-Optimization of 4,5-Dihydropyrazoles as Mono-Kinase Selective, Orally Bioavailable and Efficacious Inhibitors of Receptor Interacting Protein 1 (RIP1) Kinase.
ribose-phosphate diphosphokinase deficiency
Metabolic approaches to the treatment of autism spectrum disorders.
Sarcoma
[Thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in soft-tissue sarcoma versus capecitabine potential]
Schistosomiasis
Effect of Dihydroartemisinin-Piperaquine on the Pharmacokinetics of Praziquantel for Treatment of Schistosoma mansoni Infection.
Seizures
An incidental case of dihydropyrimidine dehydrogenase deficiency: One case, multiple challenges.
Seizures
Analysis of severely affected patients with dihydropyrimidine dehydrogenase deficiency reveals large intragenic rearrangements of DPYD and a de novo interstitial deletion del(1)(p13.3p21.3).
Seizures
Children's toxicology from bench to bed--Liver injury (1): Drug-induced metabolic disturbance--toxicity of 5-FU for pyrimidine metabolic disorders and pivalic acid for carnitine metabolism.
Seizures
Dihydropyrimidine Dehydrogenase Deficiency: Homozygosity for an Extremely Rare Variant in DPYD due to Uniparental Isodisomy of Chromosome 1.
Seizures
The anti-seizure effects of IV 5?-dihydroprogesterone on amygdala-kindled seizures in rats.
Seizures
The effects of dihydropyridine calcium channel modulators on pentylenetetrazole convulsions.
Sepsis
New approach to endotoxic and septic shock by means of polymyxin B immobilized fiber.
Shock, Septic
Endotoxin removal by direct hemoperfusion with an adsorbent column using polymyxin B-immobilized fiber ameliorates systemic circulatory disturbance in patients with septic shock.
Shock, Septic
Endotoxin removal column containing polymyxin B immobilized fiber is useful for the treatment of the patient with Vibrio vulnificus septicemia.
Shock, Septic
The severity of hyperdynamic circulation may predict the effects of direct hemoperfusion with the adsorbent column using polymyxin B-immobilized fiber in patients with gram-negative septic shock.
Skin Diseases
Diffuse hyperpigmentation of the skin: a clinicopathologic approach to diagnosis.
Skin Neoplasms
Intratumor dihydropyrimidine dehydrogenase mRNA expression levels are decreased in extramammary Paget's disease.
Spasms, Infantile
Dihydropyrimidinase deficiency in four East Asian patients due to novel and rare DPYS mutations affecting protein structural integrity and catalytic activity.
Squamous Cell Carcinoma of Head and Neck
CD44high/ESAlow squamous cell carcinoma cell-derived prostaglandin E2 confers resistance to 5-fluorouracil-induced apoptosis in CD44high/ESAhigh cells.
Squamous Cell Carcinoma of Head and Neck
Dihydropyrimidine dehydrogenase expression predicts survival outcome and chemosensitivity to 5-fluorouracil in patients with oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Effects of smoking and alcohol consumption on 5-fluorouracil-related metabolic enzymes in oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Evaluation of TS-1 based treatment and expression of thymidylate synthase and dihydropyrimidine dehydrogenase on oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Expression levels of thymidylate synthase, thymidylate phosphorylase and dihydropyrimidine dehydrogenase in head and neck squamous cell carcinoma: preliminary study.
Squamous Cell Carcinoma of Head and Neck
Expression of thymidylate synthase and dihydropyrimidine dehydrogenase in oral squamous cell carcinoma: possible markers as predictors of clinical outcome.
Squamous Cell Carcinoma of Head and Neck
Expression of thymidylate synthase and dihydropyrimidine dehydrogenase in primary oral squamous cell carcinoma and corresponding metastases in cervical lymph nodes: association with the metastasis suppressor CD82.
Squamous Cell Carcinoma of Head and Neck
Orotate phosphoribosyl transferase mRNA expression in oral squamous cell carcinoma and its relationship with the dihydropyrimidine dehydrogenase expression and the clinical effect of 5-fluorouracil.
Squamous Cell Carcinoma of Head and Neck
Study of Thymidylate Synthase (TS) and Dihydropyrimidine Dehydrogenase (DPD) Expressions on 5-Fluorouracil in Oral Squamous Cell Carcinoma
Squamous Cell Carcinoma of Head and Neck
The effect of neoadjuvant therapy on the 5-fluorouracil metabolic and relative enzymes of oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
The predictive and therapeutic value of thymidine phosphorylase and dihydropyrimidine dehydrogenase in capecitabine (Xeloda)-based chemotherapy for head and neck cancer.
Squamous Cell Carcinoma of Head and Neck
The role of dihydropyrimidine dehydrogenase expression in resistance to 5-fluorouracil in head and neck squamous cell carcinoma cells.
Squamous Cell Carcinoma of Head and Neck
Thymidylate synthase and dihydropyrimidine dehydrogenase expression in oral squamous cell carcinoma: an immunohistochemical and clinicopathologic study.
Stomach Neoplasms
5-fluorouracil sensitivity and dihydropyrimidine dehydrogenase activity in advanced gastric cancer.
Stomach Neoplasms
A Japanese Patient with Gastric Cancer and Dihydropyrimidine Dehydrogenase Deficiency Presenting with DPYD Variants.
Stomach Neoplasms
A novel mutant allele of the CYP2A6 gene (CYP2A6*11 ) found in a cancer patient who showed poor metabolic phenotype towards tegafur.
Stomach Neoplasms
A phase I study of S-1 administration and a 24-h infusion of cisplatin plus paclitaxel in patients with advanced gastric cancer.
Stomach Neoplasms
A predictive factor for the response to S-1 plus cisplatin in gastric cancer.
Stomach Neoplasms
Alternative pharmacokinetics of S-1 components, 5-fluorouracil, dihydrofluorouracil and alpha-fluoro-beta-alanine after oral administration of S-1 following total gastrectomy.
Stomach Neoplasms
Biomarker analysis in patients with advanced gastric cancer treated with S-1 plus cisplatin chemotherapy: orotate phosphoribosyltransferase expression is associated with treatment outcomes.
Stomach Neoplasms
Changes in intratumoral thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) mRNA expression in colorectal and gastric cancer during continuous tegafur infusion.
Stomach Neoplasms
Changes in thymidylate synthase and its inhibition rate and changes in dihydropyrimidine dehydrogenase after the administration of 5-fluorouracil with cisplatin to nude mice with gastric cancer xenograft SC-1-NU.
Stomach Neoplasms
Changes of gene expression of thymidine phosphorylase, thymidylate synthase, dihydropyrimidine dehydrogenase after the administration of 5'-deoxy-5-fluorouridine, paclitaxel and its combination in human gastric cancer xenografts.
Stomach Neoplasms
Choice of Capecitabine or S1 in Combination with Oxaliplatin based on Thymidine Phosphorylase and Dihydropyrimidine Dehydrogenase Expression Status in Patients with Advanced Gastric Cancer.
Stomach Neoplasms
Clinical implications of immunoreactivity of thymidylate synthase and dihydropyrimidine dehydrogenase in gastric cancer treated with oral fluoropyrimidine (S-1). Study Group of S-1 for Gastric Cancer.
Stomach Neoplasms
Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor.
Stomach Neoplasms
Correlation between thymidylate synthase and dihydropyrimidine dehydrogenase mRNA level and in vitro chemosensitivity to 5-fluorouracil, in relation to differentiation in gastric cancer.
Stomach Neoplasms
Dihydropyrimidine dehydrogenase (DPD) activity in gastric cancer tissue and effect of DPD inhibitory fluoropyrimidines.
Stomach Neoplasms
Dihydropyrimidine dehydrogenase activity and mRNA expression in advanced gastric cancer analyzed in relation to effectiveness of preoperative 5-fluorouracil-based chemotherapy.
Stomach Neoplasms
Dihydropyrimidine dehydrogenase and messenger RNA levels in gastric cancer: possible predictor for sensitivity to 5-fluorouracil.
Stomach Neoplasms
Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 may be effective against peritoneal dissemination in gastric cancer.
Stomach Neoplasms
Dihydropyrimidine dehydrogenase-related enzymes predict efficacy and adverse reactions of UFT1+cisplatin neoadjuvant chemotherapy for gastric cancer.
Stomach Neoplasms
Efficacy of laser capture microdissection plus RT-PCR technique in analyzing gene expression levels in human gastric cancer and colon cancer.
Stomach Neoplasms
Erratum to: Impact of the expression of thymidylate synthase and dihydropyrimidine dehydrogenase genes on survival in stage II/III gastric cancer.
Stomach Neoplasms
Expression of thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase, E2F-1, Bak, Bcl-X, and Bcl-2, and clinical outcomes for gastric cancer patients treated with bolus 5-fluorouracil.
Stomach Neoplasms
Gene expression of 5-fluorouracil metabolic enzymes in primary gastric cancer: correlation with drug sensitivity against 5-fluorouracil.
Stomach Neoplasms
Impact of intratumoral expression levels of fluoropyrimidine-metabolizing enzymes on treatment outcomes of adjuvant S-1 therapy in gastric cancer.
Stomach Neoplasms
Impact of the expression of thymidylate synthase and dihydropyrimidine dehydrogenase genes on survival in stage II/III gastric cancer.
Stomach Neoplasms
Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer.
Stomach Neoplasms
Impacts of fluorouracil-metabolizing enzymes on the outcomes of patients treated with S-1 alone or S-1 plus cisplatin for first-line treatment of advanced gastric cancer.
Stomach Neoplasms
Meta-analysis supporting noninferiority of oxaliplatin plus S-1 to cisplatin plus S-1 in first-line treatment of advanced gastric cancer (G-SOX study): indirect comparison with S-1 alone.
Stomach Neoplasms
Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer.
Stomach Neoplasms
Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer.
Stomach Neoplasms
Polymorphism of TS 3'-UTR predicts survival of Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel.
Stomach Neoplasms
Polymorphisms of dihydropyrimidine dehydrogenase gene and clinical outcomes of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population.
Stomach Neoplasms
Prediction of clinical outcome of fluoropyrimidine-based chemotherapy for gastric cancer patients, in terms of the 5-fluorouracil metabolic pathway.
Stomach Neoplasms
Prediction of the effect of capecitabine in gastric cancer by immunohistochemical staining of thymidine phosphorylase and dihydropyrimidine dehydrogenase.
Stomach Neoplasms
Protein-bound polysaccharide-K augments the anticancer effect of fluoropyrimidine derivatives possibly by lowering dihydropyrimidine dehydrogenase expression in gastrointestinal cancers.
Stomach Neoplasms
Quantitative double-fluorescence immunohistochemistry (qDFIHC), a novel technology to assess protein expression: A pilot study analyzing 5-FU sensitive markers thymidylate synthase, dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferases in gastric cancer tissue specimens.
Stomach Neoplasms
Quantitative measurement of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA level in gastric cancer by real-time RT-PCR.
Stomach Neoplasms
Relationship Between the DPD and TS mRNA Expression and the Response to S-1-Based Chemotherapy and Prognosis in Patients with Advanced Gastric Cancer.
Stomach Neoplasms
Role of thymidine phosphorylase and dihydropyrimidine dehydrogenase in tumour progression and sensitivity to doxifluridine in gastric cancer patients.
Stomach Neoplasms
Roles of thymidylate synthase and dihydropyrimidine dehydrogenase in tumor progression and sensitivity to 5-fluorouracil in human gastric cancer.
Stomach Neoplasms
Superior antitumour activity of S-1 in tumours with a high dihydropyrimidine dehydrogenase activity.
Stomach Neoplasms
Synergistic antiproliferative effect of mTOR inhibitors in combination with 5-fluorouracil in scirrhous gastric cancer.
Stomach Neoplasms
T85C polymorphisms of the dihydropyrimidine dehydrogenase gene detected in gastric cancer tissues by high-resolution melting curve analysis.
Stomach Neoplasms
The discrepancy in thymidylate synthase and dihydropyrimidine dehydrogenase expression depending on measurement methodologies in stage 4 gastric cancer.
Stomach Neoplasms
The expression profiles of orotate phosphoribosyltransferase and dihydropyrimidine dehydrogenase in gastric cancer and their clinical significance.
Stomach Neoplasms
The Impact of the Expression Level of Intratumoral Dihydropyrimidine Dehydrogenase on Chemotherapy Sensitivity and Survival of Patients in Gastric Cancer: A Meta-Analysis.
Stomach Neoplasms
The ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase in tumour tissues of patients with metastatic gastric cancer is predictive of the clinical response to 5'-deoxy-5-fluorouridine.
Stomach Neoplasms
Thymidylate synthase and dihydropyrimidine dehydrogenase are related to histological effects of 5-fluorouracil and cisplatin neoadjuvant chemotherapy for primary gastric cancer patients.
Stomach Neoplasms
Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in relation to differentiation of gastric cancer.
Stomach Neoplasms
Thymidylate synthase gene expression in primary tumors predicts activity of s-1-based chemotherapy for advanced gastric cancer.
Stomach Neoplasms
Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer.
Stomach Neoplasms
Thymidylate synthetase and dihydropyrimidine dehydrogenase levels in gastric cancer.
Stomach Neoplasms
[A case of gastric cancer with decreased dihydropyrimidine dehydrogenase activity]
Stomach Neoplasms
[A case of recurrent gastric cancer with dihydropyrimidine dehydrogenase (DPD) deficiency]
Stomach Neoplasms
[Combination chemotherapy of S-1 and docetaxel on advanced and recurrent gastric cancer]
Stomach Neoplasms
[Combination chemotherapy of TS-1 +cisplatin for inoperable gastric cancer]
Stomach Neoplasms
[Comparison of the efficacy and safety of capecitabine or tegafur, gimeracil and oteracil potassium capsules combined with oxaliplatin chemotherapy regimens in the treatment of advanced gastric cancer].
Stomach Neoplasms
[Dihydropyrimidine dehydrogenase expression in gastric cancer using anti-human dihydropyrimidine dehydrogenase monoclonal antibody]
Stomach Neoplasms
[Efficacy and safety of novel oral fluoropyrimidine anticancer drug, TS-1 for advanced and recurrent gastric cancer patients]
Stomach Neoplasms
[Severe bone marrow suppression during adjuvant chemotherapy for gastric cancer by S-1 and its possible relationship to dihydropyrimidine dehydrogenase deficiency]
Stomach Neoplasms
[Significance of pyrimidine nucleoside phosphorylase (PyNPase) and dihydropyrimidine dehydrogenase (DPD) in advanced gastric cancers]
Stomach Neoplasms
[Thymidylate synthase and dihydropyrimidine dehydrogenase expression and histological effects of preoperative UFT in gastric cancer patients]
Stroke
Differences in factors influencing the use of eRehabilitation after stroke; a cross-sectional comparison between Brazilian and Dutch healthcare professionals.
Stroke
Health-related quality of life after stroke: reliability and validity of the Duke Health Profile for use in Vietnam.
succinate-semialdehyde dehydrogenase [nad(p)+] deficiency
Autism: Screening of inborn errors of metabolism and unexpected results.
Tachycardia
Differential time course of the vasodilator action of various calcium antagonists.
Tachycardia
Effects of efonidipine, an L- and T-Type dual calcium channel blocker, on heart rate and blood pressure in patients with mild to severe hypertension: an uncontrolled, open-label pilot study.
Takotsubo Cardiomyopathy
The First Case of Severe Takotsubo Cardiomyopathy Associated with 5-Fluorouracil in a Patient with Abnormalities of Both Dihydropyrimidine Dehydrogenase (DPYD) and Thymidylate Synthase (TYMS) Genes.
Toxic Optic Neuropathy
Dihydropyrimidine Dehydrogenase 85T>C Mutation Is Associated With Ocular Toxicity of 5-Fluorouracil: A Case Report.
Urinary Bladder Neoplasms
Dihydropyrimidinase Like 2 Promotes Bladder Cancer Progression via Pyruvate Kinase M2-Induced Aerobic Glycolysis and Epithelial-Mesenchymal Transition.
Urinary Bladder Neoplasms
Expression level of dihydropyrimidine dehydrogenase is associated with clinical outcome in patients with T1G3 bladder cancer treated with Bacillus Calmette-Guerin.
Urinary Bladder Neoplasms
Prognostic significance of a combination of thymidylate synthase and dihydropyrimidine dehydrogenase activities in grades 1 and 2 superficial bladder cancer.
Urinary Bladder Neoplasms
Prognostic significance of thymidylate synthase activity in bladder carcinoma.
Urinary Bladder Neoplasms
The significance of dihydropyrimidine dehydrogenase (DPD) activity in bladder cancer.
Urinary Bladder Neoplasms
Thymidine phosphorylase and dihydropyrimidine dehydrogenase in bladder cancer.
Urologic Neoplasms
5-Fluorouracil-based adjuvant chemotherapy improves the clinical outcomes of patients with lymphovascular invasion of upper urinary tract cancer and low expression of dihydropyrimidine dehydrogenase.
Uterine Cervical Neoplasms
The effect of chemotherapy or radiotherapy on thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in cancer of the uterine cervix.
Virus Diseases
Prophylactic activity of dihydroheptaprenol, a synthetic polyprenol derivative, against Sendai virus infection in mice.
Whooping Cough
Endogenous modulation of ACh release by somatostatin and the differential roles of Ca2+ channels.
Whooping Cough
Roles of progesterone receptor membrane component 1 and membrane progestin receptor alpha in regulation of zebrafish oocyte maturation.
xanthine dehydrogenase deficiency
Thirteen years experience with selective screening for disorders in purine and pyrimidine metabolism.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ORGANISM
COMMENTARY
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
SOURCE
additional information
-
no detectable activity in thyroid gland, muscle, testis, brain cortex, brain gray matter and white matter
brenda
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
UNIPROT
ENTRY NAME
ORGANISM
NO. OF AA
NO. OF TRANSM. HELICES
MOLECULAR WEIGHT[Da]
SOURCE
SEQUENCE
LOCALIZATION PREDICTION
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable).
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). DPYS_HUMAN
519
0
56630
Swiss-Prot
other Location (Reliability: 4)
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PDB
SCOP
CATH
UNIPROT
ORGANISM
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBUNIT
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PROTEIN VARIANTS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
R412M
W360R
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CLONED (Commentary)
ORGANISM
UNIPROT
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REF.
AUTHORS
TITLE
JOURNAL
VOL.
PAGES
YEAR
ORGANISM (UNIPROT)
PUBMED ID
SOURCE
Kikugawa, M.; Kaneko, M.; Fujimoto-Sakata, S.; Maeda, M.; Kawasaki, K.; Takagi, T.; Tamaki, N.
Purification, characterization and inhibition of dihydropyrimidinase from rat liver
Eur. J. Biochem.
219
393-399
1994
Bos taurus, Homo sapiens, Rattus norvegicus
brenda
Geun-Joong, K.; Hak-Sung, K.
C-terminal regions of D-hydantoinases are nonessential for catalysis, but affect the oligomeric structure
Biochem. Biophys. Res. Commun.
243
96-100
1998
Geobacillus stearothermophilus, Geobacillus thermocatenulatus, Homo sapiens, Pseudomonas putida, Rattus norvegicus, Geobacillus stearothermophilus SD-1, Geobacillus thermocatenulatus GH-2
brenda
Siemann, M.; Alvarado-Marin, A.; Pietzsch, M.; Syldatk, C.
A D-specific hydantoin amidohydrolase: properties of the metalloenzyme purified from Arthrobacter crystallopoietes
J. Mol. Catal. , B Enzym.
6
387-397
1999
Agrobacterium tumefaciens, Agrobacterium sp., Paenarthrobacter aurescens, Arthrobacter crystallopoietes, Geobacillus stearothermophilus, Bacillus sp. (in: Bacteria), Parageobacillus thermoglucosidasius, Homo sapiens, Pseudomonas sp., Pseudomonas putida, Pseudomonas fluorescens, Rattus norvegicus, Agrobacterium sp. IP-I 671, Pseudomonas sp. AJ-11220, Bacillus sp. (in: Bacteria) LU 1220
-
brenda
Geun-Joong, K.; Dong-Eun, L.; Hak-Sung, K.
Construction and evaluation of a novel bifunctional N-carbamylase-D-hydantoinase fusion enzyme
Appl. Environ. Microbiol.
66
2133-2138
2000
Agrobacterium tumefaciens, Agrobacterium sp., Geobacillus stearothermophilus, Geobacillus thermocatenulatus, Escherichia coli, Homo sapiens, Pseudomonas putida, Agrobacterium sp. IP-I 671, Agrobacterium tumefaciens DSM 30147, Geobacillus stearothermophilus SD-1, Geobacillus thermocatenulatus GH-2
brenda
Schnackerz, K.D.; Dobritzsch, D.
Amidohydrolases of the reductive pyrimidine catabolic pathway: Purification, characterization, structure, reaction mechanisms and enzyme deficiency
Biochim. Biophys. Acta
1784
431-444
2008
Bos taurus, Dictyostelium discoideum, Homo sapiens, Rattus norvegicus, Lachancea kluyveri
brenda
van Kuilenburg, A.B.; Meijer, J.; Dobritzsch, D.; Meinsma, R.; Duran, M.; Lohkamp, B.; Zoetekouw, L.; Abeling, N.G.; van Tinteren, H.L.; Bosch, A.M.
Clinical, biochemical and genetic findings in two siblings with a dihydropyrimidinase deficiency
Mol. Genet. Metab.
91
157-164
2007
Homo sapiens
brenda
van Kuilenburg, A.B.; van Lenthe, H.; van Gennip, A.H.
Activity of pyrimidine degradation enzymes in normal tissues
Nucleosides Nucleotides Nucleic Acids
25
1211-1214
2006
Homo sapiens
brenda
Thomas, H.R.; Ezzeldin, H.H.; Guarcello, V.; Mattison, L.K.; Fridley, B.L.; Diasio, R.B.
Genetic regulation of beta-ureidopropionase and its possible implication in altered uracil catabolism
Pharmacogenet. Genomics
18
25-35
2008
Homo sapiens
brenda
EXTERNAL LINKS (specific for EC-Number 3.5.2.2)
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
About BRENDA
Social media
Help
Survey
Download
Contribution
Legal
Curated at
Member of
